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SUMMARY 
South Africa is in the process of Westernisation, especially in the Black male 
population, with an adaptation of a westernised diet. Morbidity and mortality 
rates have increased because of the higher incidence of cerebrovascular and 
coronary heart disease (CHD) in this population group. Dietary fibre is used 
as one of the pillars in the prevention and treatment of CHD. Previous studies 
have shown that the addition of dietary fibre to the diet can significantly 
improve metabolic profiles, induding lipid profiles, of human subjects. A 
decrease, especially in the serum total cholesterol levels, is beneficial and is 
associated with a decreased risk of the development of CHD and 
atherosclerosis. It is believed that some of these beneficial effects may be 
mediated in part by the SCFAs produced during the microbial fermentation of 
dietary fibre in the large intestine. These SCFAs include acetate, propionate 
and butyrate. 
The main objective of this study was to examine the hypothesis that exposure 
to two different combinations of short-chain fatty acids (SCFAs) , orally 
administered to a group of local westernised Black men will have beneficial 
effects on their lipid profiles. The concentration of SCFAs used was 
equivalent to that generated by the fermentation of 15g of mixed fibre. One of 
the supplements contained a mixture of acetate, propionate and butyrate in a 
ratio of 70% acetate, 15% propionate and 15% butyrate. The other 
supplement contained only a mixtore of acetate and propionate, in a ratio of 
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50% acetate and 50% propionate. It is believed that the increase of colonic 
acetate will have a positive effect on the lipid profile . 
The study was that of a randomised, placebo-controlled , double-blinded 
clinical trial. Voluntary members of the South African National Defence Force, 
Tempe Military Base, were recruited for this study, using a very strict set of 
indusion criteria. All subjects received a placebo for a period of one week 
following the collection of baseline blood samples. A second baseline blood 
sample was collected from each individual at the end of this period to ensure 
a stable baseline. Subjects were randomly assigned to three different 
intervention groups. Supplementation with the placebo, acetate-propionate-
butyrate and acetate-propionate mixtures was sustained for a period of four 
weeks following the second baseline blood collection. Lipid profiles (including 
the serum-TC, -HDL-C, -LDL-C and non-esterified fatty acids (NEFA)) , 
anthropometry, as well as some other general health markers were measured 
at each visit. Also, a 'wash-out' period of one week followed the 
supplementation phase. 
No significant changes in any of the lipid variables were observed in the 
placebo group. The acetate/propionatelbutyrate-supplement caused a non-
significant decrease in the serum TC of apprOximately 8% after four weeks of 
supplementation. In contrast, the serum-LDL-C levels significantly decreased 
(-16%; from 3.10 mmol/L ± 0.78 to 2.61 ± 0.94 mmol/L) during the same 
period of time. In the study grollp receiving a combination of acetate and 
propionate salts, a beneficial statistically Significant increase of the serum 
-
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HDL-C (from 1.21 ± 0.24 mmol/L to 1.35 ± 0.34 mmol/L) was observed , 
without any changes in the other lipid fractions. 
From the results it was evident that the inclusion of butyrate to the supplement 
was more beneficial in terms of lipid-lowering effects. These profile changes, 
associated with the additional intake of butyrate does reflect a decrease in risk 
for the future development of CHD. 
It can therefore be conduded that short-chain fatty acid supplements could be 
used to the benefit of those individuals suffering from lifestyle diseases: but 
that the most appropriate ratio of acetate, propionate and butyrate 
supplementation needs further research. 
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CHAPTER 1 
INTRODUCTION 
1.1 BACKGROUND 
Cerebrovascular disease and coronary heart disease (CHD) are among 
the most important causes of morbidity and mortality amongst South 
Africans and the people of the western world (Bradshaw et al., 1995). 
Steyn et al. (1992) found that 7.2 percent of all deaths in 1988 in South 
Africa were attributed to cerebrovascular disease and 8.7 percent to 
ischemic heart disease. Furthermore, the incidence of the western 
diseases, atherosclerosis, CHD and cerebrovascular disease is 
progressively rising in black populations in South Africa (Khan and 
Tollman, 1999; Mollentze et al., 1995). 
The risk factor prevalence for stroke and CHD alters as changes in 
lifestyle and diet occur during the process of urbanisation. Westernisation 
and migration to an urban environment contribute even further to the rise 
in the risk for the development of stroke and CHD (Bourne et al., 1993; 
Mollentze et al., 1995; Seedat et al., 1992; Solomoms and Gross, 1995; 
Steyn et al., 1991). 
Based on the 1985 census figures for the South African population, and 
1 
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the current prevalence data, it is estimated that at least 4.8 million and 3.1 
million people suffer from hypercholesterolaemia and raised low-density 
lipoprotein cholesterol levels, respectively. The South African Medical 
Association (SAMA) and the Lipid and Atherosclerosis Society of Southern 
Africa (LASSA) recognised hypercholesterolaemia as the most common 
and clinically significant lipid abnormality in South Africa (Berger and 
Marais, 2000) . It is therefore important to investigate all possible factors 
that may influence lipid metabolism, including diet. 
Prevention and cost-effective management of even moderately 
dyslipidaemia patients requires an appropriate modification of life-style: 
avoidance of tobacco smoking, participating in regular exercise, and a 
health-promoting diet (Hubbard et al., 1994; Mollentze et al., 1995; Steyn 
et al., 1987; Steyn et al. , 1992; Walker, 1995). The correct choice for 
drug treatment is a therapeutic decision, and is best done only after full 
lifestyle modification (Berger and Marais, 2000). 
The prudent low fat, high-fibre diet is regarded as one of the few 
controllable risk factors in the prevention of degenerative disease, and is 
therefore also effective in controlling known coronary risk factors 
(hyperinsulinaemia, hyperlipidaemia, hypertension, obesity, etc.) as well 
as raised clotting factors (Hubbard et al., 1994; Vorster et al., 1988; 
Vorster et al. , 1997). 
2 
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The physiological effects of dietary fibre in humans are significantly 
influenced by the degree to which the fibre is fermented in the colon 
(Bourquin et al., 1992; Cummings, 1983). Colonic fermentation results in 
the production of the short-chain fatty acids (SCFAs) acetate, propionate 
and butyrate (Bugaut and Bentejac, 1993; Muir et al., 1995). Previous 
studies have shown effects of SCFAs on the lipid metabolism (Topping 
and Wong, 1994), haemostasis (Veldman et al., 1999), Factor VII activity 
(Marckmann and Jesperson, 1996), fibrinogen metabolism (Vorster et al., 
1988) and carbohydrate metabolism (Hubbard et al., 1994). 
Both acetate and propionate concentrations are believed to be related to 
serum cholesterol levels in men (Wolever et al., 1996), and their ratio may 
predict the risk of cardiovascular disease. In a previous study, a 4-week 
acetate supplementation caused a significant reduction in serum 
cholesterol levels in hypercholesterolaemic subjects (Veldman et al., 
1999). These results strongly suggest that the effect of soluble dietary 
fibre could be partially mediated by the production of acetate. It is evident 
that acetate supplementation can therefore be useful during the treatment 
or the prevention of some clinical abnormalities, especially those 
associated with raised total cholesterol, and possibly also plasma 
fibrinogen. 
3 
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1.2 MOTIVATION 
Previous studies have shown that the addition of dietary fibre to the diet 
can significantly improve the metabolic profiles, including the lipid profiles, 
of human subjects. A decrease, especially in the serum total cholesterol 
levels, is beneficial and is associated with a decreased risk of the 
development of CHD and atherosclerosis. It is believed that some of 
these beneficial effects may be mediated in part by the SCFAs produced 
during the microbial fermentation of dietary fibre in the large intestine. 
The black population of the Free State is already in the advanced stages 
of urbanisation and westernisation (Mollentze et al. , 1995). Urbanisation 
of black populations in the Cape Peninsula represents a phase towards a 
progressively atherogenic Western diet (Bourne et al ., 1993). It is 
expected that this phenomenon may be similar in other ethnic groups of 
the South African population (Steyn et aI., 1987). Slabber et al. (1997) 
have already indicated that urban African men in the Free State Province 
show a tendency towards an atherogenic Westernised diet, characterised 
by a low-fibre, high-fat dietary intake. 
The effect of different combinations of SCFAs on the metabolic 
parameters in human subjects- has been the topic of investigation for many 
years. The intake of dietary fibre is beneficial to human health, especially 
4 
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in those individuals with a westernised lifestyle. However, the 
mechanisms involved in promoting these health effects in human subjects 
are not fully understood and remain unclear. At this stage it seems highly 
likely that the effect of dietary fibre intake is mediated by a combination of 
physical characteristics, chemical structure, as well as the metabolic 
products formed during its breakdown (Mortensen and Clausen, 1996). 
The role of SCFAs as partial mediators of reducing cardiovascular risk 
received widespread interest from as long ago as 1831 (Wrong, 1995). 
Study results are controversial and no two specific studies duplicate each 
other. To date, no conclusive evidence exists that explains the specific 
role of SCFA production during fibre fermentation, and the role it may play 
in human health (Wolever et al., 1995). 
Living in a society in the process of transforming from a prudent lifestyle to 
an increasingly unhealthy westernised lifestyle, makes it important to 
investigate any mechanisms that could improve the health status of those 
individuals at risk of developing lifestyle associated diseases. Lifestyle 
changes are much more cost-effective than medication, and in most 
cases, much less invasive. 
5 
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1.3 OBJECTIVES 
The main objective of this study is to examine the hypothesis that 
exposure to two different combinations of short-chain fatty acids (SCFAs), 
orally administered in a group of local westernised Black men, will have 
beneficial effects on their lipid profiles. The concentration of SCFAs used 
will be equivalent to that generated by fermentation of 15g mixed fibre. 
One of the supplements contained a mixture of acetate, propionate and 
butyrate in a ratio of 70% acetate, 15% propionate and 15% butyrate. The 
other supplement contained only a mixture of acetate and propionate, in a 
ratio of 50% acetate and 50% propionate. It was believed that the 
increase of colonic acetate would have a positive effect on the lipid profile. 
Differences in metabolic response to the two different supplements could 
be ascribed to the following mechanisms: 
o The ratio of acetate to propionate, as well as the absence or 
presence of butyrate which may each evoke a collaborative 
physiological response. 
Hopefully the results from this study will provide enough information to 
help develop an inexpensive but effective way of controll ing the increasing 
rise in the incidence of cardiovascular disease in the South African Black 
population group. 
6 
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1.4 STRUCTURE OF THE THESIS 
The structure of the thesis is as follows: 
Chapter 2 is an extensive literature survey, in which the most critical 
information needed to understand and interpret the hypothesis and the 
results of this study, is examined. Chapter 3 explains and gives the 
motivation behind experimental methods used during the intervention 
phase. The results of the intervention study are given in Chapter 4. In 
Chapter 5 the results of the study are discussed and compared to 
previous studies. Finally, in Chapter 6, the results, conclusions, and 
recommendations made from the intervention studies are discussed. The 
possible application of the findings to contribute to the lowering of 
cardiovascular disease is highlighted and discussed in depth. 
7 
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CHAPTER 2 
LITERATURE REVIEW 
2.1 INTRODUCTION 
Diet is a strong factor in the control of atherosclerosis, which relates to 
general vascular disease, coronary heart disease and stroke (Hubbard et 
aI., 1994). There is an especially strong relation between dietary intake 
and the prevalence of coronary heart disease in westernised cultures 
(Hubbart et aI., 1994). It is estimated that approximately 75% of South 
Africa's population were urbanised by the turn of the century (Mollentze et 
aI., (1995). The process of urbanisation affects mainly the black 
population of Southern Africa. Morbidity and mortality from cardiovascular 
diseases in the black population is expected to increase with the adoption 
of Western lifestyles and associated dietary habits (Steyn et aI., 1987; 
Gross and Monteiro, 1989; Le Roux and Le Roux, 1991; Steyn, Fourie 
and Bradshaw, 1992; Mollentze et aI., 1995; Jenkins et aI., 2001). With 
the introduction of antiretroviral therapy (ART) to the public sector, a rise 
in CHD is expected, due to cardiovascular side-effects associated with the 
long-term use of these drugs (Hadigan, 2001). 
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Coronary heart disease is preventable. Both the prevention and treatment 
of CHD depend on intervention aimed at altering its known risk factors, 
especially those associated with lifestyle, such as raised serum total 
cholesterol levels, exercise, smoking, high blood pressure, etc. (Kannel. 
and Wilson , 1995). The prudent low fat , high fibre diet is regarded as one 
of the most effective tools used for the prevention of degenerative 
westernised diseases. It is therefore also believed to be effective in 
controlling the known coronary risk factors (Hubbard et aI., 1994; Jenkins 
et al., 2002; Vorster et aI. , 1988; Vorster et aI. , 1997). 
The high fibre diet has been the subject of many investigations, and is 
believed to playa significant role in promoting human health on different 
physiological levels. A variety of specific studies has investigated 
especially the breakdown process (i.e. fermentation process) of dietary 
fibre as mediator of its effect on human metabolism. Colonic fibre 
fermentation results in the production of the short-chain fatty acids 
(SCFA), acetate, propionate and butyrate (Bugaut and Bentejac, 1993; 
Muir et aI. , 1995), each of which are believed to have a specific metabolic 
effect. 
The role of dietary fibre as a cholesterol-lowering agent has received 
widespread attention. Furthermore, it was also shown that the SCFAs 
produced after fibre ingestion have an effect on lipid metabolism (Topping 
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and Wong, 1994}. The specific effect of propionate on cholesterol 
metabolism has not yet been clarified (Beauliew and McBurney 1992; 
Breggren et al. , 1996; Kishimoto et aI. , 1995). It is believed that a 
combination of the three major SCFAs (acetate, propionate and butyrate) 
in different ratios may be more effective in lowering blood cholesterol 
levels (Wolever et aI., 1991 ; Demigne et aI. , 1994; De Wet, 1999; 
Veldman et al ., 1996). 
The literature relevant to this study will be reviewed in this chapter. The 
literature should supply the reader with sufficient information to be able to 
interpret and understand the results of this study without referral to other 
sources. 
2.2 TERMINOLOGY 
To understand some of the terminology in this chapter, it will be 
useful to provide some definitions and criteria as a framework. 
2.2.1 Atherosclerosis: Atherosclerosis is an aggregated inflammatory 
response to injury of the endothelial and the smooth muscle cells of the 
arterial wall. It can also be aefined as a complex process of thickening 
and narrowing of the arterial walls of the large- and medium-sized blood 
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vessels by the accumulation of lipids, primarily cholesterol, in the intimal or 
inner layer in combination with connective tissue and calcification 
(Meydani, 2001). 
2.2.2 Cardiovascular disease (CVO): Any disease that causes damage to the 
heart or to arteries that carry blood to and from the heart muscle (De Bono 
and Boon, 1991) 
2.2.3 Coronary heart disease (CHO): CHD is a multicausal disease manifested 
by arthrosclerosis and/or thrombosis, which involves the network of blood 
vessels surrounding and serving the heart; manifested in clinical end-
points of myocardial infarction and sudden death (Hubbard et aI., 1994; 
Krummel , 2004). 
2.2.4 Non-starch polysaccharides (NSP): All dietary fibre, except lignin, is 
plant polysaccharides and is termed non-starch polysaccharides (WHO, 
1998). NSP can be classified by solubility in water, since water-soluble 
(pectin) and water-insoluble (cereal) fibres have distinct physiological 
effects (Slavin , 1987). 
2.2.5 Risk factor: An aspect of personal behaviour or lifestyle, an 
environmental exposure, or an inborn or inherited characteristic that, on 
the basis of epidemiological evidence, is associated with a health-related 
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condition or conditions. It is not necessarily the cause of a disease but is 
an attribute or exposure that increases the probability of the occurrence of 
a disease or other specified outcome. By knowing the risk factor or 
factors of a disease, one can possibly decrease or eliminate the incidence 
of the disease by eliminating or modifying the risk factor (Last, 1988). 
2.2.6 Risk marker: A non-causal factor associated sufficiently well with a risk 
factor that it can be used as a possible reliable marker, or indicator, of the 
risk factor's presence (Last, 1988). 
2.2.7 Thrombosis: Thrombosis is the formation of a solid mass from the 
constituents of blood (platelets, fibrin and entrapped red blood cells) within 
the heart or vascular system of a living organism. Arterial thrombosis is 
common, and typically occurs after endothelial damage and local 
turbulence caused by atherosclerosis. The combination of thrombosis and 
atherosclerosis in an artery can obstruct the normal flow of blood and may 
lead to degeneration of a specific body part or organ if left untreated 
(Chandrasoma and Taylor, 1991). 
2.2.8 Stroke: Stroke is a localised neurological blood shortage due to a 
vascular lesion categorised by a sudden loss of cerebral function with 
coma due to bleeding, thrombosis or embolism of a cerebral artery 
(Chandrasoma and Taylor, 1991). 
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2.2.9 Urbanisation: The social process whereby cities grow and societies 
become more urban. The process of urbanisation is taking place in both 
less and more developed countries, but at a much higher rate in the 
former (Le Roux and Le Roux, 1991). 
2.2.10 Westernisation: Westernisation is an assimilation of western culture; the 
social process of becoming familiar with or converting to the customs and 
practices of Western civilisation (Oxford Dictionary, 2002). 
2.3 CHOLESTEROL METABOLISM 
2.3.1 Classification and metabolism of the major blood lipids 
2.3.1.1 Introduction 
The presence of cholesterol in blood was described for the first time by 
Chevreul in 1815, who named it cho/esterine (Vance and Van den Bosch, 
2000). It was only later discovered that cholesterol consists of a 
conglomerate of lipid fractions, each having its own structure and function 
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within the human body (Willett, 1998). Research into the anabolic and 
catabolic pathways of cholesterol gave new insights into the role that each 
of these fractions plays. In most cases cholesterol is treated as a "risk 
molecule" (Willett, 1998). However, it has been shown that cholesterol 
plays a very important role in normal body function, and is essential for 
maintaining life (Garrett and Grisham, 1999). 
Virtually all cells and body fluids contain some cholesterol (Warnick et a!. , 
1996). Cholesterol serves many critical functions in the brain and in the 
body. It is required for the brain to form "synapses" that permit nerve cells 
to communicate, leading to learning and memory. Cholesterol is also a 
structural component of cell membranes (Davidson, 1991). The ratio of 
cholesterol to polar lipids affects the stability, permeability and the protein 
mobility of a membrane. Cholesterol is stored in the adrenals, testes and 
ovaries, chiefly as the fatty acid ester and converted to steroid hormones. 
These hormones include the male and the female sex hormones 
(androgens and estrogens) as well as the adrenal corticoids (cortisol , 
corticosterone, aldosterone and others). In the liver, cholesterol acts as 
the precursor of bile acids (Marieb, 2001). 
A short summary of the metabolic pathways and physiological importance 
of the major blood lipid fractions will now be given in order to make the 
results of the study clear and understandable to the reader. 
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2.3.1 .2 Triglycerides and fatty acids 
Fatty acids of dietary origin are oxidised by most tissues after a meal , and 
the excess stored away in adipose tissues in the form of triglycerides. The 
stored triglycerides are degraded in the fasting state, when released fatty 
acids are the main energy source for the body (Meisenberg and Simmons, 
1998). 
Fatty acids consist of an alkyl chain with a terminal carboxyl group; and 
the simplest configuration is a completely saturated straight chain. The 
basic formula is R-COOH where 'R' stands for an alkyl chain (Rifai et al. , 
1999). Most naturally occurring fatty acids have an even number of 
carbon atoms that form an unbranched chain. Fatty chains that contain 
only carbon-carbon single bonds are referred to as saturated. Those 
molecules that contain one or more double bonds are said to be 
unsaturated (McKee and McKee, 1996). Monounsaturated fatty acids are 
fatty acids that contain one double bond. When two or more double bonds 
are present, the fatty acids are referred to as polyunsaturated (Garrett and 
Grisham, 1999). 
Fatty acids that are synthesised within the human body are known as 
nonessential fatty acids. Because mammals do not posses the enzymes 
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required to synthesise some fatty acids, and these fatty acids must be 
obtained from dietary sources, they are called essential fatty acids (McKee 
and McKee, 1996). In general , the fatty acids derived from plant seeds or 
fish lipids are more unsaturated and contain more of the essential fatty 
acids required by humans (Kaplan et al., 1995). 
Triglycerides are esters of glycerol containing three fatty acid molecules. 
Up to 95% of dietary lipids consist of triglycerides (Mann and Skeaff, 2000; 
McKee and McKee, 1996). The physical and biological properties of 
triglycerides are determined by the nature of the constituent fatty acid 
(Mann and Skeaff, 2000). Triglycerides have no charge and are 
sometimes referred to as neutral fats. Most triglyceride molecules contain 
fatty acids of various lengths, which may be either saturated, unsaturated, 
or a combination thereof (McKee and McKee, 1996). 
Dietary triglycerides are a major source of metabolic energy, accounting 
for close to 40% of the total calories in the typical Western diet. 
Triglycerides are also important as the principal storage form of energy in 
the body. Most people carry between five and twenty kilograms of 
triglycerides in their adipose tissue. These triglycerides are synthesised in 
the well-fed state, and degraded during the fasting state (Meisenberg and 
Simmons, 1998). Stored triglycerides in adipose tissue can also provide 
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insulation against cold temperatures, because fat is a bad conductor of 
heat (McKee and McKee 1996). 
2.3.1.3 Apolipoproteins 
A major characteristic of all lipids is the fact that they are not soluble in 
water. Transportation of lipids on their own in blood, which is a water-
based substance, is therefore problematic. In circulation, lipids associate 
with specific proteins, also known as the apolipoproteins, which form 
water-miscible complexes and have the ability to carry lipid-soluble 
material to the different parts of the body (Meisenberg and Simmons, 
1998). These complexes consist of a cora of neutral lipids (triglyceride 
and cholesterol esters) surrounded by a single surface layer of polar lipids 
(phospholipids and cholesterol). Coiled chains of apolipoproteins extend 
over the surface (Meisenberg and Simmons, 1998). There are five 
classes of lipoproteins which are identified according to their densities: 
high-density lipoproteins (HOL), low density lipoproteins (LOL) , very low 
density lipoproteins (VLOL) and chylomicrons (Garrett and Grisham, 
1999). Each has a distinct physiological role, and when present in 
inappropriate amounts (too high or too low), each has different adverse 
health consequences (Mann and Skeaff, 2000). Free fatty acids, which 
make up only about 2% of the total plasma lipid fraction, are transported in 
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the blood as complexes with circulating albumin (Montgomery, Conway 
and Spector, 1990). 
2.1.3.4 Low-density lipoprotein (LOLl 
VLDL acts as the main transporter of triglycerides from the liver to the 
tissues, including the muscles, the heart and the adipose tissue (Kaplan et 
al. , 1995). VLDL is generated in the liver for transportation of the 25 to 
50g of triglycerides, and smaller amounts of other lipids that are 
synthesised daily in the liver. These lipoproteins are released from the 
liver into the sinusoidal blood (Marieb, 2001). 
Approximately half of the VLDL remnants are taken up by the liver, and 
the rest transforms into intermediate-density lipoproteins (IDL). IDL are 
precursors of low-density lipoprotein (LDL), which will be discussed in the 
next section (Mann and Skeaff, 2000). 
IDL is remodelled to LDL-C in plasma (Kaplan et aI., 1995). Hepatic 
lipase (HL) hydrolyses the excess triglycerides and phospholipids in the 
IDL. HL is also responsible for the transfer of excess apolipoproteins to 
the HDL complex (Meisenberg and Simmons, 1998). 
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LDL-C has a well-defined structure. Its lipid component includes a high 
proportion of free cholesterol (8.6%) and cholesterol esters (41.9%) 
(Kaplan et aI., 1995). 
LDL-C delivers cholesterol either to the liver for bile acid formation, or to 
other tissues for metabolic breakdown. Receptors on the surface of the 
cell membranes of the liver and the tissues recognise and attach to the 
apolipoprotein of the LDL-C (Meisenberg and Simmons, 1998). The LDL-
C is then intemalised by endocytosis, and degraded by liposome enzymes 
(Rawn, 1989). The non-esterified cholesterol may be used as a structural 
component of the membranes of dividing cells; they may be converted to 
steroid hormones by the adrenal or gonad cells, or may be esterified and 
stored in the cell as esters (Kaplan et aI. , 1995). 
LDL receptors are essential for the normal metabolism of cholesterol. LDL 
receptors in the peripheral tissues bind the remnants of VLDL and 
degrade those (Meisenberg and Simmons, 1998). If the receptors are 
missing, the VLDL remnants are converted to cholesterol-rich LDL. The 
circulating concentration of LDL-C in the serum is thus greatly elevated 
(Meisenberg and Simmons, 1998). These receptor proteins play an 
integral part in cholesterol metabolism by maintaining healthy circulating 
cholesterol concentrations (Mathews and Holde, 1990) 
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The metabolism of LDL is intimately connected to the cholesterol 
metabolism (Kaplan et aI., 1995). Cholesterol is a necessary component 
of mammalian cell membranes, but the synthesis of excess cholesterol 
results in a greatly increased risk of cardiovascular disease. It is 
hypothesised that the accumulation of cholesterol ester deposits in the 
intimae of arteries is the main cause of atherosclerosis (Meisenberg and 
Simmons, 1998), and this will be discussed later in this section. 
It is hypothesised that the risk for coronary artery disease increases with 
rising plasma concentrations of LDL-C. However, it is believed that the 
risk associated with LDL-C is diminished when associated with high HDL-
C concentrations. For this reason, some laboratories calculate the ratio of 
LDL-C: HDL-C for estimating the degree of risk; a ratio of less than 3:1 is 
considered desirable (Kaplan et al., 1995; Nader et al ., 1999). 
2.3.1.5 High-density lipoprotein (HDL) 
HDL is synthesised and secreted by both the liver and intestine and 
consist of phospholipids (24%), cholesteryl esters (15%), free cholesterol 
(2%), triglyceride (4%) and apolipoproteins (Rawn, 1989) 
HDL transports cholesterol from tissues to the liver for catabolism 
(conversion to bile salts), whereas LDL transports cholesterol from sites of 
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origin to deposition in tissues, including blood vessels (Warnick et al ., 
1996). The HDL competes with LDL for binding to tissue receptors and 
may thus reduce cholesterol accumulation in the blood vessel walls. The 
concentration of the HDL cholesterol appears to be inversely related to the 
risk of cardiovascular disease (Kaplan et al., 1995). A low HDL level 
(below 0.91 mmol/L) is predictive of cardiovascular disease, even if the 
total cholesterol level is in the desirable range. The relative amount of 
HDL to total cholesterol is also important; the amount of HDL should be at 
least one quarter of the total cholesterol level (Kaplan et al ., 1995). The 
Framingham study shows that people with ratios of TC/HDL-C greater 
than 4.5 have more cardiovascular problems, and if the ratio is above 5.0, 
the risk is even greater (Garrison et al ., 1980). 
2.3.1.6 Cholesterol biosynthesis and excretion 
Slightly less than half of the cholesterol in the body is derived from 
biosynthesis. The rest is derived from dietary sources, such as meat, 
dairy products, or eggs (Kaplan et al. , 1995). Biosynthesis in the liver 
accounts for approximately 10%, and in the intestines approximately 15%, 
of the amount of biosynthesised cholesterol produced each day in the 
body (Montgomery, Conway and Spector, 1990). Cholesterol synthesis 
occurs in the cytoplasm and microbes where Acetyl-CoA is utilised for 
cholesterol biosynthesis (Nader et al ., 1999). 
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The biosynthesis of cholesterol entails the following five major steps: 
• Acetyl-CoA is converted to 3-hydroxy-3-methylglutaryl-CoA (HMG-
CoAl 
• HMG-CoA is converted to mevalonate 
• Conversion of mevalonate to an isoprene based molecule, 
isopentenyl pyrophosphate(IPP), with the concomitant loss of CO2 
• IPP is converted to squalene and 
• Squalene is converted to cholesterol (Kaplan et aI., 1989; Mathews 
and Van Holde, 1990; Nader et al., 1999; Rawn, 1989; 
Montgomery, Conway and Spector, 1990). 
Approximately 70% of plasma cholesterol is in the acyl-ester form. The 
esterification takes place almost exclusively within the HDL-complex. One 
third of the daily production of cholesterol is categorised by the shortening 
of the cholesterol side chain, and hydroxylation of the sterol nucleus. This 
results in the formation of bile acids that conjugate and are secreted into 
the gastro-intestinal tract with glycine or taurine before secretion into bile 
(Nader et al. , 1999). These bile acid-conjugates act as emulsifying agents 
that are essential for the digestion and absorption of dietary fats. Some 
cholesterol is also secreted into the bile. Both bile acids and biliary 
cholesterol are reabsorbed to some extent by the intestines, from where it 
enters the enterohepatic circulation (Kaplan et aI., 1995). 
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Normal healthy adults synthesise cholesterol at a rate of approximately 
0.5 - 1.0g/day (Meisenberg and Simmons, 1998). It is also estimated that 
the average adult consumes approximately 0.3 - 1.0g dietary cholesterol 
per day (Nader et al., 1999). This applies especially to foods such as 
meat, dairy products and eggs that are rich in dietary cholesterol (Block et 
al., 1985). A relatively constant level of cholesterol in the body «5.18 
mmollL) is maintained primarily by controlling the level of de novo 
synthesis in the liver (Kaplan et al., 1995). It is known that the dietary 
intake of cholesterol also regulates the level of cholesterol synthesis 
(Nader et aI., 1999). Cholesterol from both the diet (exogenous) and 
synthesis (endogenous) is utilised in the formation of cell membranes, the 
synthesis of the steroid hormones, as well as in the synthesis of bile acids. 
The greatest proportion of cholesterol is used for bile acid synthesis 
(Kaplan et al., 1989). 
The synthesis and utilisation of cholesterol must be tightly regulated in 
order to prevent over-accumulation and an abnormal deposition within the 
body. Of particular clinical importance is the abnormal deposition of 
cholesterol-rich lipoproteins in the coronary arteries. These depositions, 
eventually lead to atherosclerosis (Nader et al. , 1999). 
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2.3.1.7 Atherosclerosis 
Atherosclerosis is defined by the presence of athermanous plaques, with 
characteristic lesions in the intima of large arteries (De Bono and Boon 
1991 ). 
The typical athermanous plaque contains a core of cholesterol esters 
surrounded by an area of fibrosis. The plaque impairs blood flow by 
narrowing the lumen of the artery, and it can lead to such complications as 
calcification, haemorrhage into the plaque and thrombus formation (Woolf 
1998). This process takes place over a long period of time and causes 
thickening of the arterial wall, eventually leading to closure of the artery, in 
turn leading to tissue damage within the body part/organ supplied with 
oxygenated blood by the relevant artery (Chandrasoma and Taylor, 1991). 
The resulting partial blockage of a coronary artery may cause chest pains 
(angina) (Davidson, 1991). A complete blockage of a heart artery, results 
in necrosis of the affected muscle area and eventually heart attack 
(Edwards and Bouchier, 1991). Ideally, circulating serum-LDL-C levels 
should be less than 3.4 mmol/L and ideally less than 2.6 mol/L (Kaplan et 
aI., 1995). 
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2.4 LlPIDAEMIA 
2.4.1 Introduction 
Lipidaemia is defined as a clinically alteration in the circulating lipids and 
lipoproteins predisposing to CHD and related disorders. In practice, the 
most important and common is hypercholesterolaemia (Berger and 
Marais, 2000). The term hyperlipidaemia emphasises the importance of 
excess lipid in generating the adverse consequences of the common lipid 
(lipoprotein) disorders (Ahmed et al., 1998). The chief exception is a low 
HDL concentration with its independently atherogenic effect: a high HDL 
level (>1.5 mmol/L) is generally protective (Berger and Marais, 2000). 
Lipidaemia is common in westernised, industrialised communities. In 
South Africa, CHD is most widespread in the Indian and White groups, 
with a somewhat lower incidence in the Coloured community (Wyndham, 
1982). CHD in the black population is still relatively uncommon, but risk 
factors for the possible emergence of future CHD are already apparent, 
including hypertension, diabetes, hyperlipidaemia, obesity and tobacco 
smoking (Steyn et al., 1991). 
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2.4.2 Classification and diagnosis 
The lipoprotein phenotype is most conveniently classified in terms of 
hypercholesterolaemia, hypertriglyceridaemia or as a mixed picture with 
cholesterol and triglyceride levels more or less equally elevated (Warnick 
et aI., 1996). 
Table 2.1 Classification of lipidaemia (Berger and Marais, 2000) . 
Desirable Hypercholesterol- Mixed Hypertriglyceridaemia 
lipid emia Hyperlipid-
profile1 Moderate Severe aemia Moderate Severe 
TG <or - 1.5 < 1.5 < 1.5 1.5 - 5.0 5 - 15 >15 
TC <or = 5.0 5 -7.5 > 7.5 > 5.0 <5 -increased > 5.0 
LDLC <or = 3.0 3.0 - 5.0 > 5.0 Variable Variable Variable 
HDLC >or = 1.2 Variable Variable Low Low Low 
Concentrations are expressed in mmol/L 
2.4.2.1 Secondary lipidaemia 
In secondary lipidaemia the genetic constitution of a person is normal or 
contains only minor gene defects, both the environment and the 
underlying incidental disease brings out the lipidaemia. Causes of 
secondary lipidaemia may be the following: 
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• An unhealthy diet (high saturated fat, high cholesterol, low fibre and 
high-energy intakes) can directly or indirectly bring about a moderate 
lipidaemia, often contributing to the primary disorders mentioned above 
(Meisenberg and Simmons, 1998). 
• Diseases that cause hypercholesterolemia include hypothyroidism, 
nephrotic syndrome and obstructive jaundice. Diseases that predispose 
to hypertriglyceridaemia include truncal obesity, diabetes and Cushing's 
syndrome (Berger and Marais, 2000). 
• Pregnancy causes a rise in plasma cholesterol concentration and may 
induce severe hypertriglyceridaemia in susceptible women (Punnonen, 
1977). 
• Drugs that influence the lipid profile in deleterious ways include steroids, 
some beta-blockers, diuretics at high doses, retinoic acid derivatives and 
protease inhibitors used in HIV treatment (Amprenavir, Agenerase) 
(Pronsky, 2001). 
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2.4.3 Management of hyperlipidaemia 
• 
• 
The two key elements in the management of hyperlipidaemia are: 
Lifestyle modification, which is desirable in virtually all patients and, 
the use of appropriate lipid modifying drugs in those patients at 
high risk (Gibbons et al., 2003). However, this will not be 
discussed in this chapter. 
The main targets of lifestyle or behavioural modification are: cessation of 
tobacco use, a healthy diet, regular aerobic exercise and, where indicated, 
loss of weight (Russel , 1998). 
2.4.3.1 Cessation of tobacco use 
This is the single most important therapeutic action in patients with 
hyperlipidaemia (Ahmed et al ., 1998; Berger and Marias, 2000). 
2.4.3.2 Regular aerobic exercise 
The minimum effective target is 30 minutes of brisk walking, 3 times 
weekly. A preferable minimum target would be 4 hours of moderate 
exercise per week, spread over 5-6 sessions. A planned exercise 
programme should be appropriate to age, gender and clinical status - a 
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cardiology opinion should be obtained where clinical CHD is present or 
suspected. The exercise should elevate heart rate to about 75% of age-
related maximum heart rate (220 beats/minute minus age in years) 
(Ahmed et al., 1998; Berger and Marais, 2000). 
2.4.3.3 Prudent diets 
Dietary intervention should be the first step in the treatment of 
dyslipidaemia and the main purpose of a prudent diet is to maintain or 
achieve a desirable body mass and optimal health, as well as to lower 
raised TC, LDL-C and TG levels and raise the HDL-C level (Wolmarans, 
2004:0nline). As discussed, LDL cholesterol is conclusively linked to 
CHD development. Consequently, LDL cholesterol is the primary target 
for intervention efforts (Krummel, 2004). It is recommended that a 
moderate hypercholesterolaemia without CHD receives dietary treatment 
for at least 4-12 weeks before drug treatment is introduced. In those with 
hypercholesterolaemia and CHD, drug treatment should be introduced 
earlier (Wolmarans, 2004). Berger and Marais (2000) recommend that a 
person with a cholesterol level between 5.0 - 7.5 mmol/L, in the absence 
of additional risk factors, be treated with a prudent diet. 
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The main elements of a prudent or anti-coronary diet are: a reduction of 
saturated fat, cholesterol and energy intake relative to the typical 
Westernised intake (Berger and Marais, 2000). 
Current dietary guidelines recommend a total daily intake of at least 20 to 
30g for adults, with 25 percent of the fibre being soluble fibre (National 
Cholesterol Education Program [NCEP], 2001). These levels may be 
attained with a proposed six or more daily servings of grain products and 
five or more daily servings of fruit and vegetables. Adding 3g per day of 
soluble fibre from oat bran can reduce total cholesterol by 0.13 mmol/L 
(Blake and Triplett, 1995). A higher daily intake of soluble fibre promotes 
a further modest reduction of the cholesterol values. A high-fibre, low fat 
diet also provides other beneficial effects, including improved glycaemic 
control , weight reduction and the prevention of diverticular disease, and 
possibly, prevention of colorectal cancer (Anderson and Gustafson, 1987). 
In addition to lowering total fat intake, intake of alcohol should be reduced 
if clinically indicated, and in hypertriglyceridaemia states, also simple 
carbohydrates. Ideal weight may be defined by a BMI < 25 kg/m 2 in the 
general population (Berger and Marias, 2000). 
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2.5 DIETARY FIBRE 
2.5.1 Introduction 
The specific role of dietary fibre on cholesterol metabolism will now be 
discussed. 
2.5.2 Classification, chemistry and sources of dietary fibre 
Dietary fibre is generally defined as plant material , mainly derived from 
plant cell walls, that is resistant to digestion by human gastrointestinal 
enzymes (Hunt et al., 1993). Food chemists prefer to define fibre as 
"lignin and non-starch polysaccharides (NSP), where NSP includes 
celluloses, hemicelluloses, pectin gums and mucilage, found in food" 
(Hunt et al., 1993). All dietary fibres, except for lignin, are plant 
polysaccharides and are therefore termed NSP (Vorster et al. , 1990). 
NSP are not hydrolysed by the small-intestinal enzymes and are a suitable 
substrate for the bacterial production of the short-chain fatty acids 
(SCFAs) acetate, butyrate and propionate in the large bowel , together with 
incompletely digested starch, lactose and proteins (Cummings et al., 
1987; Camp et al., 2003). The fermentability of NSP is related to 
important clinical effects (Camp et al. , 2003) 
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Soluble fibres (pectins, gums) are largely fermented, while insoluble fibres 
are more difficult to degrade The gases CO2, H2, CH4 and water are 
produced as by-products (Brand-Miller, 2000). 
2.6 SHORT-CHAIN FATTY ACIDS 
2.6.1 Characteristics of SCFAs 
SCFAs can be described as saturated unbranched alkyl monocarboxylic 
acids of 2-4 carbon atoms as shown in Table 2.2 (Wrong, 1995). SCFAs 
are biochemically more closely related to carbohydrates than to fats. 
Some of them are not constituents of natural fats, and they are not "fatty", 
as the layman envisages the term, as they are completely miscible in 
water (Wong, 1995). The three major SCFAs (acetate, propionate and 
butyrate) are moderately strong acids, with pK values of about 4.8. 
Intestinal contents are more alkaline than this, so SCFAs are 
predominantly present within the intestine as negatively charged anions 
and not as free acids (Wrong, 1995), and create a slightly acidic pH level 
(Fleming et al., 1991). In all regions of the colon, acetate, propionate and 
butyrate account for 90-95 present of the total SCFAs, with acetate being 
the principal anion (Mortenson and Clausen, 1996). Serum acetate is 
derived primary from colonic fermentation, serum butyrate primarily from 
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endogenous fatty acid metabolism, and serum propionate from both 
exogenous and endogenous sources (Wolever et al., 1997). 
Table 2.2 Short chain fatty acids (Morensen and Clausen, 1996) 
Chemical formula 
CH3-COOH 
CH3-CH2-COOH 
CH3-(CH2)2-COOH 
2.6.2 Production of SCFAs 
Trivial name 
Acetate 
Propionate 
Butyrate 
NSPs, defined as indigestible complex carbohydrates, remain in the ileum 
but are partly hydrolysed by bacteria in the colon (Hubbard et al ., 1994). 
Much of the research into the benefits of NSP consumption on human 
health has focused on the actions of fibre in the large intestine. These 
actions depend largely on the extent to which fibre is fermented by the 
residing population of anaerobic bacteria, and on the physical 
characteristics of unfermented fibrous material (Bourquin et al., 1992). 
The main substrates for the c010nic fermentation in healthy individuals are 
NSP (cellulose, hemiceliuloses and pectin) ( Mortensen and Clausen, 
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1996; Camp et al ., 2003). Bacterial fermentation of one gram of 
monosaccharide yields approximately 10 mmol of organic acid 
(Scheppach et al., 1992). Colonic fermentation leads to the production of 
SCFAs, certain gases (carbon dioxide, methane, hydrogen), and microbial 
cell mass (Bourquin et al., 1992). Furthermore, total SCFA production 
from fermentation is the greatest for oat bran (Bourquin et al., 1992). 
Anderson (1995) also supports this in demonstrating that serum acetate 
levels produced from oat bran peak twice as high as those observed with 
intakes of beans or wheat bran. The SCFAs vary widely in their relative 
proportions, depending upon the fibre source in the diet (Bugaut and 
Bentejac, 1993). Table 2.3 indicates the SCFA molar percents from 24-
hour fermentation of dietary fibres in, in vitro incubation systems 
inoculated with fresh human faecal flora (Bugaut and Bentejac, 1993). 
After absorption, each of the primary SCFAs produced (acetate and 
butyrate) is metabolised by the body and many biological effects of SCFAs 
have been reported (Bourquin et al., 1992). The SCFAs that escape 
colonic metallisation enter the hepatic portal blood, where their 
concentration varies in a wide range, depending on the production rates, 
(Cheng et al. , 1987). SCFAs influence carbohydrate and lipid 
metabolism, and may therefore contribute to the protective effect of NSP 
against degenerative western diseases associated with fibre intake 
(Burkitt and Trowell , 1986; Wolever et al. , 1991). SCFAs also contribute 
to the energy needs of the body and play a potential role in protection 
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against the development of colonic disorders (Mortensen and Clausen, 
1996). SCFAs in human faeces, following consumption of different 
defined polysaccharides, have been measured on the average, in the 
molar ratio of acetate to propionate of 53:27:20 (Bugaut and Bentejac; 
1993; Savage, 1987). Levels of all three SCFAs varied significantly during 
the day, tending to decrease after breakfast, and to increase transiently 
after lunch and dinner. Both the time of day and glucose tolerance status 
affect SCFA levels in non-diabetic humans (Wolever et al., 1997). 
Table 2.3 After a 24hr fermentation of different dietary fibres in vitro the 
following SCFA molar percents were found (Bugaut and Bentejac, 
1993). 
Substrate Acetate Propionate Butyrate 
Pectin 81 11 8 
Gum arabic 68 23 9 
Oat bran" 65 19 16 
Wheat bran" 63 16 21 
Celluloseb 53 21 26 
a oc-cellulose and hemicelluloses are 7% and 19% dry total dietary fibre, respectively, in oat bran 
and 19% and 38%, respectively, in wheat bran. 
b 48-h fermentation. 
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2.6.3 Absorption and the metabolism of SCFAs 
SCFAs produced in the large intestine in substantial amounts are 
absorbed and subsequently utilised by the animal as a substrate of energy 
metabolism (Engelhardt, 1995). According to Mortensen and Clausen 
(1996), an increase of SCFA absorption is equal to 150-360 Kcal/day of 
metabolised energy. Western diets, where SCFAs are absorbed in the 
gut, provide three to nine percent of their total energy requirements 
(Green 2000). SCFAs, especially butyrate, are metabolised to different 
extents in the mucosa of the large intestine (Engelhardt, 1995). 
2.6.3.1 Absorption 
SCFAs in vivo appear to be absorbed rapidly and nearly completely. 
Clearance rates of SCFAs have generally been observed to increase with 
chain length, even though there are differences between the rates in the 
distal and proximal colon (Bugaut and Bentejac, 1993; Engelhardt, 1995). 
Studies done on the mechanism for SCFA absorption supported trans-
cellular absorption as a major pathway (Mortensen and Clausen, 1996). A 
suggested model for trans-cellular transport can be either through para-
cellular or cellular transport (Engelhardt, 1995, Mortensen and Clausen, 
1996). This also accounts for the large number of observations describing 
the dependence of SCFA absorption rates on luminal pH and PC02, as 
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well as on the fluxes of water, protons and inorganic ions (Cr, HC03-, Na+ 
and K') through the colonic mucosa (Engelhardt, 1995; Mortensen and 
Clausen, 1996). 
Para-cellular transport is defined as non-active transport that should 
depend on the trans-epithelial difference. However, the para-cellular 
pathway is not a major site for SCFA absorption (Mortensen and Clausen, 
1996). The possible mechanism of cellular uptake can be through passive 
diffusion or facilitated diffusion (Mortenson and Clausen, 1996). The 
trans-mural movement of SCFA is a concentration-dependent, passive 
diffusion process, whereby SCFAs are, at least in part, transported in the 
protonated form. Hydrogen ions, which are needed for SCFA protonation 
may be available from Na+/H+ exchange and from hydration of luminal 
CO2 to HC03- and H+ (Bugaut and Bentejac, 1993). A relationship 
between SCFA absorption and bicarbonate secretion has frequently been 
observed (Engelhardt, 1995). SCFAs may also be transported in the 
ionised form via a SCFA-HC03- exchange mechanism, also known as the 
facilitated diffusion process (Bugaut and Bentejac, 1993; Mortensen and 
Clausen, 1996). The precise mechanism for the absorption process of 
SCFAs is still unknown. 
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2.6.3.2 Metabolism 
Several studies have shown that SCFAs, once taken up, are metabolised 
at a high rate inside the ceacal and colonic mucosal cells (Bugaut and 
Bentejac, 1993). The SCFAs that escape colonic metabolisation enter the 
hepatic portal blood, where their concentration varies over a wide range, 
depending on their intestinal production rates, and therefore on the diet. 
The relative proportions of the three major acids in the portal blood reflect 
the relative proportions of those found in the intestinal contents (Bugaut 
and Bentejac, 1993). After absorption, the body metabolises each of the 
primary SCFAs differently. 
2.6.3.2.1 Acetate metabolism 
For metabolism, acetate requires activation with coenzyme-A (CoA). This 
process requires the equivalent of two molecules of ATP. This process 
may even start as early as within the colonocytes of the gut. Mitochondrial 
acetyl-CoA is used in the citric acid cycle (Krebs cycle) for ATP 
production, for the synthesis of ketone bodies (Henning and Hird, 1972) 
and, after transfer to the cytosol , for the synthesis of lipids (Dietschy and 
Spady, 1983). 
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Based on the concentration in the peripheral and portal blood, 
approximately 75% of the acetate is extracted during a single pass of 
blood through the human liver (Dankert et al ., 1981 ; Peters et aI., 1992). 
However, not all SCFAs taken up by the liver are metabolised there. Also, 
after ethanol administration, studies show the liver to be a net producer of 
acetate (Lundquist et al ., 1962). Under these conditions, a variety of 
human tissues, including skeletal muscle (Lindeneg et al., 1964) and brain 
(Juhlin-Dannfelt, 1977) utilise considerable quantities of acetate. Changes 
in the blood acetate reflect, at least qualitatively, changes in colonic 
acetate production. Short-term starvation reduces serum acetate, 
whereas infusion of acetate into the rectum causes a dose-dependent 
increase in blood acetate (Wolever et aI. , 2002). 
In humans, only acetate of the SCFAs reaches the circulation beyond the 
liver in appreciable quantities. The venous plasma concentration of 
acetate in normal humans, as measured by gas-liquid chromatography, is 
about 50 !lmoll L in the fasting state (Scheppach et ai , 1991). Acetate in 
the peripheral blood is not entirely derived from the colon , since several 
tissues both produce and consume acetate simultaneously (Bleiberg et 
al ., 1992) 
The utilisation and the metabolic effects of SCFA may depend on the rate 
and the route of administration. For example, acetate given orally appears 
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to have no effect on the plasma concentration of the pancreatic 
glucagons, but given rectally, it has repeatedly been shown to increase 
the concentration of this peptide hormone in the circulation (Scheppach et 
al., 1988; Stephen et al. , 1989). Rectal, oral and intravenous acetate 
each lowered the concentration of plasma free fatty acids (FFA) 
(Scheppach et al., 1988). This observation is consistent with the effect of 
SCFAs in sparing long-chain fatty acids from oxidation in humans 
(Lundquist et aI., 1962) and in reducing lipolysis in the rat adipocytes in 
vitro (Nilsson and Belfrage, 1978). The antilipolytic effect may be 
mediated by the same mechanism that occurs when ketone bodies reduce 
lipolysis in adipose tissue (Robinson and Williamson, 1980). 
2.6.3.2.2 Propionate metabolism 
Propionate metabolism has been extensively studied in ruminants where it 
is a major glucose precursor. Much less is known of its role in man. 
Propionate can be found in portal blood, although some may be 
metabolised in the colonic epithelium and may be a differentiating factor, 
but with less power than butyrate (Champ et al., 2003). 
Propionate is utilised primarily by the liver, where it is used as substrate 
-
for gluconeogenisis (Bugaut and Bentejac, 1993) and it has also been 
suggested as a potential modulator for cholesterol synthesis (Chen et al ., 
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1984). Under normal conditions, propionate is completely metabolised by 
the liver (Remesy et aI. , 1995). This process is certainly favoured by 
facilitated diffusion, which is efficient even in the presence of relatively low 
propionate concentrations. (Fafounoux, Remesy and Demignne, 1985). 
Propionate metabolism depends on the bioavailability of vitamin B12 or 
biotin (Chiang and Mistry, 1974). If propionate metabolism increases, the 
requirement for vitamin B1 2 increases (Cullen and Oace, 1989). 
Propionate supplemented diets have been shown to lower blood 
cholesterol in rats (Chen et al ., 1984, IIlman et al ., 1988) and pigs (Boila 
et al., 1981), but in humans the effects are less clear. In a double-bind 
placebo controlled study of ten female volunteers fed with 7.5g sodium 
propionate daily for seven weeks, there was no change in serum 
cholesterol, but HDL cholesterol increased, as did triglycerides (Venter et 
al., 1989). As discussed earlier in this chapter, an increase in HDL-C is of 
beneficial value. In a similar study, lasting one week, no effect on 
cholesterol was seen but glucose levels were lowered (Todesco et al., 
1991). In another study, nine healthy males, whose initial cholesterols 
were all > 5.5 mmollL, were given 5.4g propionate daily for 15 days and 
showed a decrease in cholesterol and in LDL cholesterol levels, whilst 
acetate was without effect (Stephen, 1994). 
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To overcome the objections that oral propionate does not reflect the true 
physiology of propionate produced by fermentation in the hindgut, two 
studies using rectal or colonic infusions of propionate have been 
undertaken (Wolever et al ., 1989; Wolever et al. , 1991). Propionate had 
no effect on slightly raised serum cholesterol in short-term studies. Other 
studies have however shown that propionate inhibits hepatic cholesterol 
synthesis by the redistribution of cholesterol from plasma to the liver 
(Chen et al., 1984; IIlman et al ., 1988). 
2.6.3.2.3 Butyrate metabolism 
Hepatic uptake of butyrate is considered to be practically complete under 
any physiological conditions. Butyrate is the preferred energy source for 
colonocytes and is thus extensively metabolised by the colon (Roediger, 
1982). Butyrate uptake could be facilitated by the presence of a butyrate 
binding protein in the cytosol (Remesy et aI. , 1995). Butyrate is 
exclusively metabolised in the mitochondria (carnitine-independent source 
of acetyl-CoA) and it is a potentially ketogenic substrate during the post 
absorptive period. Butyrate activation is probably mediated by medium-
chain acyl-CoA synthetase(s) (Remesy et al ., 1995). Furthermore, 
butyrate leads to ketone body production and could be used as an 
important respiratory fuel in preference to acetate, propionate, glutamine, 
glucose and ketone bodies (Bugaut and Bentejac, 1993). High 
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concentrations of butyrate inhibit propionate utilisation. It is therefore 
suggested that butyrate probably thwarts some of the inhibitory effects of 
propionate (Demignne et al., 1986). 
2.6.4 Effects of SCFAs on lipid metabolism 
Dietary intervention studies show that the greatest reduction in the 
percentage of blood lipids and lipoproteins are seen in a high fibre 
vegetable diet with reductions in total cholesterol , LDL cholesterol and the 
ratios of total to HDL cholesterol, as well as LDL to HDL cholesterol. The 
high fibre vegetable diet is also associated with a Significantly higher 
output of total SCFAs, when compared to other diets containing more fats 
and proteins (Jenkins et al . 2001). 
It is known that water-soluble fibres such as psyllium, pectin, guar gum 
and oat gum have potent hypocholesterolaemic effects. Early research 
has led to the suggestion that SCFAs might contribute to the 
hypocholesterolaemic effects of these water-soluble fibres (Anderson and 
Chen, 1979) 
Two popular hypotheses explaining the possible mechanisms though 
which these fibres exert hypocholesterolaemic effects were developed 
over time, and are: 
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• Soluble fibres bind bile acids in the intestine, alter lipid and bile-
acid absorption and increase faecal loss of the bile-acids (Anderson 
and Siesel , 1990; Jenkins et al. , 2001). 
• Soluble fibres are fermented in the colon to SCFAs, which are 
absorbed into the portal vein and attenuate hepatic cholesterol 
synthesis (Anderson and Siesel, 1990). This would then cause the 
liver to convert more cholesterol to bile acids, thereby reducing 
body cholesterol (Anderson and Siesel, 1990). 
Hara et al. (1999) examined possible mechanisms involved in the 
cholesterol-lowering effects of SCFAs in rats. They found that SCFAs 
produced by caecal fermentation were possibly involved in lowering 
plasma cholesterol levels by negating the counteractive induction of 
hepatic cholesterol synthesis caused by an increase in bile excretion. 
The liver is the principal site of the propionate metabolism and cholesterol 
synthesis. Methylcellulose, a modified polysaccharide resistant to 
microbial metabolism, and which, therefore, is not fermented in the colon 
to SCFAs, had no effect on the plasma cholesterol , hepatic cholesterol 
synthesis and faecal excretion of bile acids (Topping et al., 1988). 
However, with guar gum, a fermentable fibre, hydrolysis had the same 
decreasing effects on cholesterol levels, as did intact guar gum. A tenfold 
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increase of caecal SCFAs contents was observed with both kinds of 
substrates. Veldman et al. (1999) found that supplementation with 
acetate alone caused significant decreases in the total cholesterol , and 
LDL cholesterol. Such results suggest that action of absorbed SCFAs on 
the hepatic and peripheral metabolism of the cholesterol may be an 
alternative mechanism for the effect of fermentable carbohydrates on the 
bile cholesterol concentrations. 
It has been suggested that propionic acid, and possibly even acetate, may 
reduce plasma cholesterol levels (Briges et al ., 1992). Wolever et al . 
(1989) suggests that acetate might reduce cholesterol synthesis by 
reducing circulating free fatty acids (FFA). Veldman et al. (1999) found 
that both acetate and pectin supplementation decreased FFA significantly. 
If cholesterol synthesis is decreased through a decrease in FFA, it is 
evident that both acetate and pectin could decrease total cholesterol by 
the same mechanism. Strong associations between changes in levels of 
LDL cholesterol and changes in the levels of serum acetate also support ) 
the hypothesis that changes in the SCFAs contribute to the 
hypocholesterolaemic effects of soluble fibres (Anderson, 1995). Wolever 
et al . (1995), however, found that acetate is incorporated into the plasma 
lipids, and that propionate resulting from colonic fermentation inhibits this 
process. 
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Wolever et al. (2001) found that although acetate is the preferred 
substrate for hepatic fatty acid and cholesterol synthesis, it does not 
increase the overall rate of lipid synthesis. Nevertheless, the incorporation 
of acetate into cholesterol and fatty acids is inhibited by propionate, and 
the addition of propionate to rectal infusions of acetate reduces acetate 
incorporation into serum lipids, especially triacylglycerols, in humans. 
Thus the ratio of acetate to propionate produced in the colon may be an 
important determinant of the effect of colonic SCFAs on blood lipids. 
In another study during which propionate capsules were given to healthy 
subjects for a period of seven weeks (Venter et al ., 1990), propionate use 
did not affect serum cholesterol levels, but significantly increased HDL 
cholesterol by 11 percent when compared to the control changes. 
Todesco et al. (1991) showed a significant difference in the serum lipids in 
subjects who consumed bread containing 9.9g of propionate per day to 
the subjects who consumed white bread without propionate. Total 
cholesterol, LDL cholesterol , LDL cholesterol tended to be lower while 
triglycerides tended to be higher after propionate-containing bread 
consumption. 
Wolever et al . (2002) suggest that the adaptation of blood lipid responses 
occurs partly in response to high fibre diet, and to a long-term adaptation 
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in SCFA production from colonic fermentation of unabsorbed dietary 
carbohydrates, but is cautious in attributing the changes in the blood lipids 
over time to true physiologic adaptation. Most dietary studies suggest that 
fasting blood lipids respond maximally to dietary changes within 2-4 weeks 
(Garg et al., 1994; Jenkins et al., 1993). 
2.7 Summary 
It is evident that urbanisation and the adoption of a westernised diet is 
responsible for the rise in cardiovascular disease in the black population of 
South Africa. 
Diet is one of the controllable factors in the treatment and the prevention 
of westernised diseases such as CHD. On the basis of current 
understandings, it is apparent that western diets do not contain enough 
NSP, and that the average intake falls below the recommended level. 
Fermentation of NSP results in production of SCFAs, which have 
beneficial effects on coronary risk factors (lipid profiles). 
SCFAs fermented in the colon can be successfully substituted with the 
same results. There is, however, a controversy surrounding SCFA 
supplementation. 
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CHAPTER 3 
METHODS AND TECHNIQUES 
3.1 INTRODUCTION 
The main objective of this study is to determine the effect of a 
combination and ratio difference of short-chain fatty acids on the lipid 
profile in men of the South African National Defence Force (SANDF). To 
achieve this objective, the study design, selection of subjects, 
measurements, and statistical analyses, as well as the limitations of the 
study, will be discussed in this chapter. 
3.2 ETHICAL CONSIDERATIONS 
The study was approved by the Ethics Committee of the Faculty of 
Health Sciences of the University of the Free State (UFS) (Ethics 
Number: 227/98). All subjects participating in the study gave their written 
consent (Appendix 1). 
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3.2 STUDY DESIGN 
The study design was that of a randomised, placebo-controlled, double-
blinded clinical trial as represented in Figure 3.1 . 
Subjects falling within a predetermined set of inclusion criteria (see 3.3.1 
below) were included in the study. Two baseline blood samples and 
other information were obtained (day 0 and day 8) in order to ensure an 
accurate reflection of the variables, and a stable baseline. All subjects 
received equal amounts of the placebo for a period of one week prior to 
the intervention period of the study, in order to obtain a stable baseline 
(day 8). After baseline two, subjects were randomised into three equal 
groups with 25 subjects in each group. Group 1 received a placebo 
supplement and group 2 (experimental 1) and 3 (experimental 2) were 
supplemented with various combinations of SCFAs. Supplementation 
with the various combinations of short-chain fatty adds and the placebo 
was then sustained for 4 weeks (day 8 - 36). A washout period followed 
the intervention period, during which all subjects again received the 
placebo supplement for a period of one week (day 43). 
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RECRUITMENT 
Screening (n - 120) 
75 Subjects recruited according to inclusion I exclusion criteria 
MEASUREMENTS AT BASELINE 1 (day 0) 
75 subjects 
• Blood sampling for metabolic parameters 
* Anthropometric measurements 
* Blood pressure 
Food frequency questionnaire (FFQ) (dietary data) 
Placebo supplement 
MEASUREMENTS AT BASELINE 2 (day 8) 
Blood sampling for metabolic parameters 
* 
Anthropometric measurements 
* 
Blood pressure 
* 
Starting of 4 weeks supplementation 
Group 1 (n=25) Group 2 (n=25) Group 3 (n=25) 
Placebo 70% acetate 50% acetate 
SCFA free 15% propionate 50% propionate 
15% butyrate 
MEASUREMENTS AFTER 4 WEEKS (day 36) 
Group 1:n = 17 Group 2:n = 19 Group 3:n = 18 
* Blood sampling for metabolic parameters 
* Anthropometric measurements 
* Blood pressure 
* Food frequency questionnaire (dietary data) 
COMPLETION OF STUDY (day 43 - washout period) 
* Blood sampling for metabolic parameters 
* AnthropometriC measurements 
Figure 3.1 Schematic representation of the study design 
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Food frequency questionnaires (FFQ- Appendix 3) were used to 
determine dietary intake at baseline 1 (day 0), and after the intervention 
period (day 36) . The study was undertaken at a time specifically 
designed to minimise possible seasonal effects on human metabolism. 
3.3 SUBJECTS 
3.3.1 Subject recruitment 
ApprOximately one hundred and twenty members of the SANDF were 
recruited to partiCipate in the study voluntarily. Subjects were recruited in 
the following manner: 
• Subjects had to volunteer 
• A recruitmenUscreening questionnaire was completed 
(Appendix 2) 
• Blood pressure, glucose and cholesterol levels above a specified 
level, as discussed later in this section, were taken. 
3.3.2 Screening 
Screening ensures that participants meet eligibility criteria and comply 
with the requirements of the study (Dennis and Kris-Etherton, 1991). 
Screening for this study to-ok place during an individual interview, using a 
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questionnaire (Appendix 2). A trained fieldworker was present during 
the interview to translate any issues which the subjects might not have 
understood. 
3.3.3 Inclusion criteria 
Subjects for this study were induded/chosen according to the following 
inclusion criteria. 
• males aged between 18 and 45 
• blood glucose levels below 5.8 mmol/L 
• no alcohol abusers « 3 drinks / day or <28g alcohol/day) 
• no subjects using medication for chronic diseases 
• subjects had to have been permanent staff of the SANDF for at 
least one year prior to the study. 
3.3.4 Sample size 
75 Volunteers were recruited to partiCipate voluntarily in the study. 
The total sample size (3 x n) was determined by the Department of 
Biostatistics at the University of the Free State (UFS). Power 
calculations showed that 15 individuals per group would be sufficient 
for measuring significant changes in cholesterol levels. A number of 
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25 individuals per group would be sufficient to allow for a drop-out 
rate of 10 per group. This estimate is realistic. 
3.4 MEASUREMENTS 
3.4.1 Metabolic parameters 
The following metabolic parameters were measured during this study: 
• Serum total cholesterol, serum low density lipoprotein-cholesterol 
(LDL-C), serum high density lipoprotein-cholesterol (HDL-C), 
serum triglycerides and non-esterified fatty acid (NEFA), as 
markers for the lipid profile (Willet 1998). 
• total serum protein, serum albumin, a full blood count plasma 
fibrinogen, and haemoglobin as markers for health and nutritional 
status (Lindsey, 1996) 
• fasting serum glucose and insulin levels as indicators of 
glycometabolic control (Donnelly, 1996; Franz, 2004). 
• Normal accepted ranges for the metabolic variables for black 
-
populations, according to the Department of Chemical Pathology 
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and Haematology at the University of the Free State, are 
summarised in Table 3.1 . 
Table 3.1 Normal ranges for metabolic Indicators used in this study 
Metabolic indicators Normal range 
Total cholesterol 3.0 - 5.2 mmollL 
Triglycerides 0.3 - 2.0 mmollL 
NEFA 0.1 - 0.9 mmollL 
LDL-C 2.02 - 3.37 mmollL 
HDL-C 0.98 - 1.83 mmollL 
Glucose 3.6 - 5.6 mmollL 
Insulin 5.0 -25 ~IU/mL 
Total protein 64 -84 gIL 
Albumin 34 -52 gIL 
3.4.2 Anthropometric status 
Height, weight, hip and waist circumference were measured to determine 
the anthropometric status of volunteers. Height and weight were used to 
calculate the body mass index (BMI). BMI can be used as an indicator of 
obesity, and is associated with an increased risk of developing health 
problems (Earl and Borra4 2000). BMI is classified as follows: 
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• Underweight <1 8.5 kg/m
2 
• Normal weight 18.5 - 24.9 kg/m
2 
• Overweight 25.0 - 29.9 kg/m
2 
• Obesity, dass I 30.0 34.9 kg/m
2 
• Obesity, dass II 35.0 - 39.9 kg/m
2 
• Obesity, dass III ~40 kg/m2 
(adapted from Laquatra, 2004). 
3.4.3 Blood pressure 
Blood pressure is a dynamic variable, and was measured as an indicator 
of the subjects' physical and emotional state at the time of the 
measurement (De Bono and Boon, 1991). Hypertension, which refers to 
high arterial blood pressure and is represented by raised systolic and 
diastolic blood pressure (Seedat et at, 1993) is dassified as follows: 
Normal blood pressure < 140/90. mmHg 
• Borderline hypertension > 40/90 mmHg < 160/95 mmHg 
• Hypertension > 160/95 mm Hg 
(adapted from De Bono and Boon, 1991). 
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3.4.4 Dietary intake 
The dietary intake of subjects was measured by means of a standardised 
food frequency questionnaire (Appendix 3). The prudent diet guidelines 
were used as a reference for macronutrient intake (Wolmarans et al., 
1988). 
3.4.5 Blood sampling 
Biochemical information was obtained using the appropriate blood. The 
analysis was performed in the laboratory of the School of Health 
Technology at the Central University of Technology, Free State, using 
standardised procedures. 
The coefficient of variation (CV) of the methods was determined for each 
set of measurements for the control of accuracy and reproducibility of the 
methods. The CV for each method was calculated as follows: 
CV = [standard deviation]1 [mean] x 100 
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3.4.6 Phlebotomy 
Venipuncture was done by trained personnel using a plastic tube holder 
(bulldog), a tourniquet, Precision Glide needles ™ (Becton Dickinson, 0.8 
x 38mm), and 70% alcohol swabs (Medi-Swab*) into pre-vacutained 
tubes. The subject was seated, his/her arm supported and venipucture 
was performed in the antecubital area of the arm where the medial 
cubital, cephalic and basilica veins are dose to the surface. 
3.4.7 Blood sample preparation 
a. Serum 
5 ml of whole blood was left to dot at room temperature. These samples 
were centrifuged at 2800 x g for 20 minutes in order for the serum to 
separate. Serum samples were frozen at -72°C in Eppendorf® vials 
(Safelock micro test tubes cat. no. 0030120.094 US nO.1,404,655, 
Canadian nO.315.460) 
b. EDTA blood 
5mL blood was obtained in pre-treated I<:JEDTA-tubes (VAC-U-TEST). 
After using some of the sample for determining full blood counts, the 
remainder of the sample was centrifuged for 15 minutes at 2800 x g and 
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the plasma stored at -72°C in Eppendorf@ vials (Safelock micro test 
tubes cat. no. 0030120.094 US no.1 ,404,655, Canadian no.315.460). 
c. Citrate plasma 
Citrated blood (1 mmol/L citrate, pH 4.5-4.8 plus 9 ml venous blood) was 
centrifuged at 2800 x g for ten minutes to prepare citrated plasma and 
stored at -72°C in Eppendorf@ vials (Safelock micro test tubes cat. no. 
0030120.094 US no.1,404,655, Canadian no.315.460). Citrate acts as 
an inhibitor of early activation of factor V and VII. Citrate plasma was 
used for the analyses of clotting factors (plasma fibrinogen). 
3.4.8 Measurement of metabolic parameters 
The methods used to measure the above-mentioned metabolic 
parameters will be discussed in the next section. 
a. Serum glucose 
Serum glucose was determined in duplicate by using an enzymatic 
colorimetric assay (Glucose GOO-PAP; Roche Diagnostics GmbH, 
Mannheim, Germany; Cat. no. 1448668) on the Roche/Hitachi 902 auto 
analyser. This method is based on the oxidation of glucose to 
gluconolactone in the presence of atmospheric oxygen. The resultant 
hydrogen peroxide oxidises 4-aminophenazone and phenol to 4-(p-
benzoquinone-monoiminoj-phenazone in the presence of peroxidase 
58 
© Central University of Technology, Free State
(POD). The colour intensity of red dye is directly proportional to the 
glucose concentration, and can be measured photometrically. This 
method was calibrated against the Calibrator for Automated Systems 
(cat. no. 759 350, Roche Diagnostics GmbH, Mannheim, Germany). 
Precinorm U/normal values (cat. no. 171 735, Roche Diagnostics GmbH, 
Mannheim, Germany) and Precipath U/abnormal values (cat. no. 171 
760, Roche Diagnostics GmbH, Mannheim, Germany) were used as 
control serum. The CV for the method was 1.41 %. 
b. Serum insulin 
Serum insulin was determined in duplicate by means of an enzyme 
immunoassay for the quantitative measurement of insulin in human 
serum (Cat no. EIA-2935, manufactured by DRG Instruments GmbH 
Germany). The DRG insulin enzyme-linked immunosorbent assay 
(ELISA) is a solid phase two-site enzyme immunoassay. It is based on 
the direct sandwich technique, in which two monoclonal antibodies are 
directed against separate antigenic determinants on the insulin molecule. 
During incubation insulin in the sample reacts with biotin-conjugated anti-
insulin antibodies and anti-insulin antibodies bound to the inside of a 
microtitration well. A simple washing step removes the unbound biotin 
labelled antibody. 
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During the second incubation step streptavidin peroxidase enzyme 
complex binds to the biotin-anti-insulin antibody. The bound horseradish 
peroxidase complex is detected by its reaction with 3,3' ,5,5' -
tetramethylbenzidine. The reaction is stopped by adding acid to the 
sample to give a colorimetric endpoint that is read 
spectrophotometrically. The CV for the method was 6.8 %. 
c, Serum-total protein (TP) 
Total protein was determined using a colorimetric assay supplied by 
Roche Diagnostics GmbH, Mannheim, Germany (cat. no. 1929917). 
Divalent copper reacts in an alkaline solution with protein peptide and 
bonds to form the characteristic purple-coloured buiret complex. The 
colour intensity is directly proportional to the protein concentration which 
can be determined photometrically, This method was calibrated against 
the Calibrator for Automated Systems (cat. no. 759 350, Roche 
Diagnostics GmbH, Mannheim, Germany). Precinorm Ulnormal values 
(cat. no. 171 735, Roche Diagnostics GmbH, Mannheim, Germany) and 
Precipath U/abnormal values (cat. no. 171 760, Roche Diagnostics 
GmbH, Mannheim, Germany) were used as control serum. The CV for 
this method was 1.5 %. 
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d. Serum-total albumin 
Serum albumin was determined in duplicate using the colorimetric 
Bromocresol-green (BCG) method supplied by Roche Diagnostics 
GmbH, Mannheim, Germany (cat. no 197 0909) on the Boehringer 
Mannheim Hitachi 902 chemistry analyser. Albumin complexates with 
bromocresol-green at a pH of 4.2. The intensity of the coloured complex 
is directly proportional to the albumin concentration in the sample. The 
method was calibrated against the Calibrator for Automated Systems 
(cat. no. 759 350, Roche Diagnostics GmbH, Mannheim, Germany). 
Precinorm U/normal values (cat. no. 171 735, Roche Diagnostics GmbH, 
Mannheim, Germany) and Precipath U/abnormal values (cat. no. 171 
760, Roche Diagnostics GmbH, Mannheim, Germany) were used as 
control serum. The CV for this method was 2.1 %. 
e. Serum total cholesterol 
Serum total cholesterol was determined using an enzymatic colorimetric 
test. The method was performed using reagents supplied by Roche 
Diagnostics GmbH, Mannheim, Germany (cat. no 1491458). Cholesterol 
is determined enzymatically using cholesterol esterase and cholesterol 
oxidase. Cholesterol esters are cleaved by the action of cholesterol 
esterase to yield free cholesterol and fatty acids. Cholesterol is 
converted by oxygen with the aid of cholesterol oxidase to choles-4-4-
one and hydrogen peroxide. Hydrogen peroxide created forms of a red 
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dye by reacting with 4-aminophenazone and phenol under the catalytic 
action of peroxidase. The colour intensity is directly proportional to the 
concentration of cholesterol, and can be determined photometrically. 
This method was calibrated against the Calibrator for Automated 
Systems (cat. no. 759 350, Roche Diagnostics GmbH, Mannheim, 
Germany). Precinorm U {normal values (cat. no. 171 735, Roche 
Diagnostics GmbH, Mannheim, Germany) and Precipath U lab normal 
values (cat. no. 171 760, Roche Diagnostics GmbH, Mannheim, 
Germany) were used as control serum. The CV for the method was 0.33 
percent. 
f. High density lipoprotein cholesterol (HDL-C) 
Low-density lipoproteins (LDL) was precipitated qualitatively by the 
addition of phosphotungstic acid in the presence of magnesium ions (Cat 
no.CH 2652 Randol<, Crumlin, UK). HDL-C was isolated by 
centrifugation of the sample. The cholesterol content of the isolate was 
then determined, using exactly the same method as described for the 
measurement of the TC as described above. The intensity of the 
produced colour was measured photometrically at 365nm. A special 
control was used as standard (Boehringer Mannheim-Roche Diagnostic, 
Mannheim, Germany). Values are expressed in mmol/L. The CV for the 
method was 1.9%. 
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g. %HDL-C 
The %HDL-C was determined using the following calculation: 
%HDL-C = HDL-C X 100 
TC 
h. Low density lipoprotein cholesterol (LDL-C) 
LDL cholesterol (mmoI/L) was determined using the following calculation 
(Randol<, Crumlin. UK): 
LDL cholesterol = total cholesterol - triglycerides - HDL cholesterol 
2.2 
Values were expressed in mmollL. The CV for the method was 1.9%. 
i. Serum-triglycerides 
Serum triglyceride concentration was determined by using a colorimetric 
assay supplied by Roche, Diagnostics, Germany (cat. no. 1730711). 
The method is based on the work by Wahlefeld using a lipoprotein lipase 
from micro-organisms for the rapid and complete hydrolysis of 
triglycerides to glycerol, followed by oxidation to dihydroxyacetone 
phosphate and hydrogen peroxide. The hydrogen peroxide thus reacts 
with 4-aminophenazone and 4-chlorophenol under the catalytic action of 
peroxidase to fonn a reet-dye (Trinder endpoint reaction). The method 
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was calibrated against the Calibrator for Automated Systems (cat. no. 
759 350, Roche Diagnostics GmbH, Mannheim, Germany). Precinorm U 
Inormal values (cat. no. 171 735, Roche Diagnostics GmbH, Mannheim, 
Germany) and Precipath U labnormal values (cat. no. 171 760, Roche 
Diagnostics GmbH, Mannheim, Germany) were used as control serum. 
The CV for this method was 1.3%. 
j. Non-esterified fatty acids (NEFA) 
The optimised colorimetric assay for the enzymatic determination of free 
fatty acids (non-esterified fatty acids, NEFA) in duplicate was used to 
determine the free fatty acid concentration (cat. no. FA 115, Randox 
Laboratories Ltd, Crumlin, United Kingdom) in plasma samples. The 
method involves the formation of Acyl-CoA, AMP and PPi in the 
presence of Acyl-CoA Synthetase. The Acyl-CoA is converted to 2,3,-
trans-Enoyl-CoA and H20 2 in the presence of Acyl-CoA Oxidase. The 
H20 2 is reacted with a chromogen in the presence of peroxidase, which 
can be measured photometrically. The intensity of the colour of the 
chromogen is directly proportional to the concentration of the NEFA in 
the sample. 
k. Plasma fibrinogen 
Plasma fibrinogen was determined using the Dade Behring Coagulation 
Analyser with Multifibrin®-U reagent (Cat. No. OWZG 15; Dade Behring, 
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Marburg, Germany). Fibrinogen Standards 1-4 (Cat. No. OWCS 11 ; 
Dade Behring, Marburg, Germany) were used for calibration purposes. 
Control Plasma N for normal values (Cat. No. ORKL 17; Dade Behring, 
Marburg, Germany) and for Control Plasma P for pathological ranges 
(Cat. No. OUPZ 13; Dade Behring, Marburg, Germany) were induded for 
control purposes. 
I. Full blood counts determination 
A full blood count was performed on the Coulte~ MicroDiff 18, cell 
counter. 
3.4.9 Anthropometric measurements 
Anthropometry involves obtaining physical measurements of an 
individual, then relating these measurements to standards that reflect, 
among others, health and nutritional status (Lee and Nieman, 1996; 
Gibson 2000). All the anthropometric measurements were taken by the 
trained researcher throughout the study. For standardisation purposes 
the anthropometric measurements were measured by the same 
fieldworker throughout the study. 
a. Weight 
Body weight was measured according to a standard method described 
by Lee and Nieman (19ge) and Chanton et al. (1996) using a calibrated 
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Seca digital electronic scale which weighs to the nearest 0.1 kg. The 
weight of the subjects wearing light clothing and no shoes was measured 
before blood samples were collected prior to breakfast, and after the 
subjects went to the bathroom. The weight was measured at baseline 
and after four weeks of supplementation. 
b. Height 
Standing height of subjects wearing light dothing and no shoes was 
measured to the nearest 0.5 cm using a statiometer as described by 
Charlton et al. (1996). The subjects stood with their feet together, heels 
against the measuring board . They stood erect, neither slumped nor 
stretching, looking straight ahead, without tipping the head up or down. 
The top of the ear and outer corner of the eye were in a line parallel to 
the floor ("Frankfort plan"). The top of the statiometer was lowered to 
rest flat on the top of the head. 
c. Body Mass Index (BMI) 
8MI was calculated using the standard formula: (weight (kg) I height 
(!'li)) (Pressman and Adams, 1990, Hammond, 2004). 
d. Waist and hip circumferences 
Waist and hip circumferences were measured in duplicate, around the 
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smallest and widest part of the waist and hips respectively, to the nearest 
0.1 cm. Waist circumference was measured at the lowest level of the 
umbilicus. Hip circumference was measured at the largest diameter 
below the umbilicus or the maximum circumference over the buttocks 
taken perpendicularly on the axial line of the trunk as described by 
Chanton et al. (1996). 
e. Blood pressure 
Blood pressure was recorded using a sphygmomanometer and a 
stethoscope before blood samples were collected, according to the 
methods used by DeBono and Boon (1991). The subjects were seated 
with the back supported. The cuff was applied to the right upper arm, 
with the bag over the branchial artery and connected to a mercury or 
aneroid manometer. The stethoscope was placed over the branchial 
artery and the cuff was inflated to a level well above that which abolishes 
the Korotkov sounds. The pressure in the cuff was then allowed to drop 
slowly and the point of return of the sounds was taken as the systolic 
pressure. As the pressure dropped further, the sounds became louder 
and then usually suddenly became muffled and later disappeared, at 
which stage the diastolic pressure was measured. Three intermittent 
readings were taken at two-minute intervals, and the lowest value was 
recorded. 
67 
© Central University of Technology, Free State
3.5 QUESTIONNAIRES 
Questionnaires used in this study induded a screening questionnaire 
(Appendix 2), a food frequency questionnaire (Appendix 3) and a 
tolerance questionnaire (Appendix 4). 
3.5.1 Screening questionnaire 
The screening questionnaire was developed to select subjects with 
specific characteristics according to the inclusion and exclusion criteria of 
the study. Questions regarding age, activity level, smoking habits, 
alcohol intake and a medical history were recorded (Appendix 2). 
3.5.2 Food Frequency Questionnaire (FFQ- Appendix 3) 
The purpose of dietary assessment is to estimate food consumption of 
dietary intake in individuals or groups of people (Nelson, 2000). Usual 
dietary intake is valuable in assessing nutritional status when used in 
combination with biochemical, anthropometric and clinical data (Lee and 
Nieman, 1996; Dwyer, 1998). Data obtained from this questionnaire will 
not be discussed in this document. 
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3.5.3 Tolerance questionnaire 
The tolerance questionnaire (Appendix 4) was completed after the study 
to determine whether any of the subjects experienced any possible side-
effects during the intervention that could be related to the contents of the 
capsules. Volunteers were asked if they had experienced any of the 
following symptoms: nausea, constipation, diarrhoea, decrease or 
increase in appetite, and whether the number of capsules consumed was 
acceptable. 
3.5.4 Standardisation of the FFQ 
The fieldworkers were trained to ask the same questions and to use the 
FFQ, the food models and other dietary survey aids in the same way, to 
obtain reliable results. 
3.6 SUPPLEMENTS 
3.6.1 Capsules 
Capsules were filled by QuattroMed, in Bethlehem, Free State. The 
capsules were enterically coated, to ensure that the capsules would pass 
the stomach and dissolve-in the large gut. The capsules were designed 
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in such a way that they contained equal amounts of the sodium and 
calcium salts, in order to prevent excess intake of these ions by subjects. 
The molar concentrations of SCFAs were calculated using 15g of non-
digested glucide, which produce 1.78 mol SCFA per mol hexose, as 
reference (Roberfroid et aI., 1993). 
3.6.1 Supplement 1 
Supplement 1 contained a mixture of: 
• 70% acetate, consisting of 0.4618g sodium and 0.2989g calcium acetate 
(2 x 0.057685185 mol SCFA), 
• 15% propionate , made up of 0.0698g sodium and 0.0677g calcium 
propionate (2 x 0.012361111 mol SCFA), and 
• 15% butyrate, made up of 0.0801g sodium and 0.0779g calcium butyrate 
(2 x 0.012361111 mol SCFA). 
The capsules each weighed 1.0562g. Each subject consumed 8 
capsules per day. 
3.6.2 Supplement 2 
Supplement 2 contained a mixture of: 
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• 50% acetate, consisting of 0.3299g sodium and 0.2135g calcium acetate 
(2 x 0.041203704 mol SCFA); 
• 50% propionate, made up of 0.2328g sodium and 0.2257g calcium 
propionate (2 x 0.041203704 mol SCFA), and 0% butyrate. 
The capsules weighed 1.0019g each. Each subject consumed 8 
capsules per day. 
3.6.3 Supplement 3 
The placebo was filled with sodium chloride. calcium chloride and CMC 
sodium carmelel DV (S), a non-fermentable form of cellulose. The 
capsules weighed approximately 1.0288g each. Subjects had to take 8 
placebo capsules per day. 
3.7 FIELDWORKERS AND STANDARDISATION OF TECHNIQUES 
3.7.1 Fieldworkers 
The fieldworkers used in this study included: 
• A qualified nurse and a group of trained medical personnel of the 
SANDF. These people were responsible for taking blood samples 
and measuring blood pressure. 
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• Four qualified dieticians who were standardised to use the 
validated food frequency questionnaire. 
• A trained primary health care worker of the SAN OF who helped 
with the translation of the questionnaires where necessary. 
• A post-graduate student trained to take anthropometric 
measurements. 
3.7.2 Standardisation of blood sampling 
The nurse and the operational medical personnel received special 
training in the measurement of blood pressure and drawing of the various 
blood samples. This was necessary, as some research techniques were 
different to those used for everyday medical purposes, especially the 
quantity of blood taken on each visit. Some samples used for the 
determination of specific metabolic parameters had special prerequisites 
that had to be adhered to, i.e. blood tubes that should be taken without 
stasis; as well as some samples that should be mixed well with the 
contents of the blood tube in order to prevent clotting of the blood sample 
within the tube (citrated blood tubes, etc.). The time-limits for blood 
sampling were also adhered to strictly (all samples were taken before 10 
a.m.) in order to prevent daily variation on metabolic parameters from 
having an impact on the study results. 
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3.8 PILOT STUDY 
A pilot study was conducted on a group of 20 volunteers. However, all 
measurements were simulated and no blood samples were taken from 
the individuals. The adapted FFQ were also tested on five members by 
the qualified dieticians to apply earlier training in order to ensure that all 
the questions of the FFQ were clear, and to identify any other problems 
that could occur. 
3.9 MANAGEMENT OF THE STUDY 
Daily management is an essential component of quality assurance 
(Dennis and Kris-Etherton, 1992). A strong, capable investigative team is 
the key to avoiding problems that might prejudice the study. Good 
management includes: organisation, communication, dear delineation 
and coverage of duties and responsibilities, contingency plans, and 
procedures for dealing with problems (Dennis and Kris-Etherton, 1992). 
The following management measures were taken to ensure that the 
objectives of the study were met: 
• Volunteers were informed of the content of the study, the 
importance of their roles, as well as the practical arrangements 
that might help the 1I0w of the study. 
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• A placebo group was included in the study to exclude the effect of 
other factors such as seasonal changes, etc. on the measured 
metabolic variables. 
• A late breakfast was arranged at the mess after the blood samples 
were drawn to make sure that volunteers attended the sample 
collection in a fasting state. 
• The Department of Biostatistics at the UFS randomly divided the 
subjects into the experimental and placebo groups. 
• The capsules were counted beforehand by an outsider 
participating neither in the project nor in the execution of any 
aspects of the project. All the capsules looked similar. Packages 
were numbered by an outsider and kept in a sealed envelope in 
his office. The blind information was made available once all the 
results were supplied to the statistician in charge. This ensured 
that both partiCipants and researchers were blinded for the 
duration of the study. 
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• The SANDF section head of the members ensured that the 
capsules were taken every day. Each subject's capsules were 
kept in his own bag, clearly marked with his number. 
• It was crucial that the subjects be continuously motivated 
throughout the study. The following measures were taken by the 
researcher in order to keep the subjects motivated: 
• The researcher encouraged the members with each visit to take 
their supplements daily. Subjects were given supplements on a 
daily basis when they had their meals at the mesh. This was also 
a measure of compliance. Each subject had their own bag of 
capsules kept at the mesh and given to them under direct 
supervision of the mesh supervisor, dietician in charge of the 
study, or mesh attendant. The bags were transparent and were 
marked clearly with each participant number. All capsules were 
exactly similar in shape and colour. Capsules were counted 
beforehand and the exact number of capsules was given to each 
participant during their daily visit to the mesh. Compliance to the 
study was therefore very high and in most cases, only subjects 
that dropped out did not have a 100% compliance. Drop-outs 
included mainly those individuals relocated to other units within 
the defence force. -One subject died during the study period, due 
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to accidental death. This death was in no way related to the 
study. 
• Informal social functions were arranged at regular intervals. 
• The subjects were followed up weekly. This helped with the 
evaluation of the progress of the study, as well as with the 
participation of the subjects; and also identified any unwanted but 
inevitable problems. 
• At the end of the study, each subject received a gift in 
acknowledgement for taking part in the study. 
3.10 STATISTICAL ANALYSIS 
Results were summarised using means, standard deviations (SD), 
numerical variables and frequencies and percentages (categorical 
variables). Changes within groups from baseline one (day 8) to baseline 
two (day 36); and from baseline 2 (day 8) to the end of the intervention 
period (day 36), were compared using the paired-t-test, with a p-Ievel of 
< 0.05 as significant. Differences in changes between groups were 
measured using the independent t-test method. The analyses were 
performed by the Department of Biostatistics, UFS. 
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3.11 LIMITATIONS OF THE STUDY 
A sample of 75 subjects who met the inclusion criteria during the 
screening phase was initially recruited for the study. Only 58 subjects 
(Group 1: 17; Group 2: 21; Group 3: 20) completed the study. However, 
it was estimated that a group of 15 volunteers per group would have 
been sufficient for statistical changes to be measured as dinically 
significant. Also, this study had a very short intervention period. Long-
term effects of SCFAs on the lipid profiles may differ from the short-term 
effects. It is therefore suggested that the study be repeated with a longer 
intervention period. 
77 
© Central University of Technology, Free State
CHAPTER 4 
RESULTS 
4.1 INTRODUCTION 
The results of the randomised clinical intervention trial will be presented 
in this chapter. The aim is to report the changes in lipid profiles and 
other measured metabolic parameters after supplementation with two 
different combinations of SCFAs and a placebo. Background 
characteristics of the group as a whole will be presented; after which 
the group will be broken down into the respective supplement groups. 
Comparisons between the metabolic effects of the supplements within 
the different study groups will then be presented. Baseline two (day 8) 
will be used as a reference baseline to compare possible changes in 
the lipid parameters of subjects. As explained in the Methods chapter, 
subjects were all given a placebo for one week for standardisation 
purposes. 
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4.2 BASELINE CHARACTERISTICS OF THE STUDY GROUP AS A 
WHOLE 
4.2.1 Demographic characteristics of the study group as a whole 
All the volunteers of this study were members of the South African 
National Defence Force (SANDF), Tempe, having been based in 
Bloemfontein for at least one year prior to the study. The subjects all 
lived on the premises of the SANDF, and followed exactly the same 
basic diet, supplied at the mess-hall of the SANDF. A registered 
dietician monitored the dietary intake of the study group in order to limit 
any major changes in intake during the study. 
All subjects were male, between the ages of 18 and 45 years. The 
mean age of the study group was 27 years. None of the subjects had 
used any chronic medication, had a history of previous illness (such as 
coronary heart disease, diabetes, etc.) or had had known or visible 
physical disabilities prior to the study. 
A full-time medical team on the premises of the SANDF monitored any 
changes in the health of subjects. Subjects had access to this team 
both during and after the study. Any drugs, medication or supplements 
taken during the intervention phase were reported on the subject files. 
Subjects were examined for any possible side-effects that may have 
been directly or indirectly caused by the respective supplements 
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(allergic reactions, etc.). Subjects were asked to report suspected 
side-effects or observations or anything out of the ordinary. Records 
were kept of these reports. 
4.2.2 Anthropometric measurements of the study group as a whole (see 
Table 4.1) 
No overweight or obese subjects were included in the study group. 
The Body Mass Index (BMI) of the group as a whole fell within the 
estimated limits of the normal reference range for healthy adult males 
(18.5 to 24.9 kg/m2) . All other anthropometric measurements reflected 
the healthy physical dimensions of the study group. 
The mean blood pressure of the study group at baseline 1 was 
118 ± 12 over 83 ± 12 mmHg. 
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Table 4.1 Anthropometric measurements of the study group as a whole 
VARIABLE I Baseline 1 Baseline 2 
Height X 170.5 
(em) SO 6.50 
Weight X 66.3 67.2 
(em) SO 8.90 8.90 
BMI X 22.8 23.0 
(kg/m2 ) SO 2.30 2.40 
Waist X 77.2 77.7 
(em) SO 6.9 7.1 
HIP X 95.4 95.9 
(em) SO 5.9 6.2 
SBP X 118 118 
(mmHg) SO 11 12 
OBP X 81 83 
(mmHg) SO 16 12 
(X - mean; so - standard deviation; BMI - Body Mass Index; SBP - Systolic Blood 
Pressure; DBP = Diastolic Blood Pressure) 
4.2.3 Lipid profiles of the study group as a whole (see Table 4.2) 
The serum-Total Cholesterol (TC) of the study group at day 8 (baseline 
2) was 4.46 ± 0.84 mmol/L. The High-Density Lipoprotein Cholesterol 
(HDL-C) comprised 28.5 ± 7.3% of the circulating serum-total 
cholesterol. The fasting serum-triglyceride (TG) level for this group 
was 1.17 ± 0.61 mmol/L. Fasting non-esterified fatty acid (NEFA) 
levels were 0.368 ± 0.170 mmol/L. 
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Table 4.2 Lipid profiles of the study group as a whole 
VARIABLE Baseline 1 Baseline 2 
TC X 4.36 4.46 
(mmoI/L) SO 0.88 0.84 
TG X 1.17 1.17 
(mmoI/L) SO 0.50 0.61 
HOL-C X 1.41 1.24 
(mmoI/L) SO 0.47 0.28 
LOL-C X 2.35 2.67 
(mmoI/L) SO 0.83 0.78 
%HOL-C X 33.7 28.5 
(%) SO 9.5 7.3 
NEFA X 0.48 0.37 
(mmoI/L) SO 0.27 0.17 
(X - mean; SO - standard deviation ;TC - serum-Total Cholesterol , TG - serum-
Triglycerides ; HDL-C = serum·High·Density Lipoprotein Cholesterol ; LDL-C = 
serum-low-Density Lipoprotein Cholesterol; %HDL-C = HDL·CfTC • 100 ; NEFA = 
Non-Esterified Fatty Acids) 
4.2.4 Glycometabolic indicators of the study group as a whole (see 
Table 4.3) 
The fasting serum-glucose level of the group as a whole at day 8 
(baseline 2) was 5.47 ± 0.88 mmol/L. The group had a fasting serum-
insulin level of 13.7 ± 21.3 IJIU/mL 
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Table 4.3 Glycometabolic indicators of the study group as a whole 
VARIABLE Baseline 1 Baseline 2 
Glucose X 5.32 5.47 
(mmoI/L) SO 0.83 0.88 
Insulin X 10.7 13.7 
(j.lIU/mL) SO 16.6 21.3 
(X = mean; SO = standard deviation) 
4.2.5 Other metabolic variables of the study group as a whole (see 
Table 4.4) 
Some more general metabolic indicators of the health status of 
subjects were induded in the laboratory analyses. The serum Total 
Protein (TP) concentration at day 8 (baseline 2) was 79.9 ± 5.6 gIL, of 
which the albumin made up 44.8 ± 2.6 gIL. 
Blood cell counts were also measured as part of a full blood count, 
and the results are reported in Table 4.4. The haemoglobin levels at 
day 8 (baseline 2), measured as part of the full blood count, were 
15.8 ± 1.5 g/dl. The concentration of plasma-fibrinogen, an acute 
phase protein, was 3.28 ± 1.26 gIL. 
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Table 4.4 Other metabolic variables of the study group as a whole 
VARIABLE Baseline 1 Baseline 2 
TP X 80.50 79.90 
(giL) SO 6.30 5.60 
Albumin X 45.20 44.80 
(giL) SO 3.80 2.60 
TPIAlbumin X 1.88 1.79 
SO 0.47 0.13 
WBC X 5.95 5.66 
(x103/I.1L) SO 2.05 1.51 
RBC X 5.16 5.17 
(x103/I.1L) SO 0.53 0.57 
Haemoglobin X 15.9 15.8 
(g/dL) SO 1.1 1.5 
Fibrinogen X 2.77 3.28 
(giL) SO 0.91 1.26 
Albumin! X 17.7 16.1 
Fibrinogen SO 4.8 5.8 
(X - mean; SD - standard deviation; TP - serum-Total Protein; WBC - White Blood 
Count; RBC = Red Blood Count) 
4.3 RESULTS OF THE INTERVENTION STUOY 
4.3.1 The Placebo Group 
4.3.1.1 Changes in the anthropometrical measurements of the placebo 
group (see Table 4.5) 
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No significant changes in any of the anthropometrical variables 
were measured in the placebo group during the intervention phase 
of the study. 
Table 4.5 Changes in the anthropometrical measurements of the placebo 
group 
VARIABLE OayO DayS Day 22 Oay36 Day 43 
Height X 1.72 
(em) SO 0.07 
Weight X 68.6 69.6 69.9 69.6 69.7 
(kg) SO 10.9 10.5 11.5 10.3 10.8 
BMI X 23.2 23.4 23.7 23.6 23.6 
(kg/m2) SO 2.9 2.8 3.0 2.7 2.8 
Waist X 78.9 80.2 78.2 78.4 78.1 
(em) SO 8.6 8.7 7.7 8.1 7.4 
Hip X 95.9 96.9 98.1 97.5 98.0 
(em) SO 8.8 9.2 6.0 6.5 6.8 
SBP X 119 124 121 116 115 
(mmHg) SO 15 15 14 11 11 
OBP X 85 87 85 83 83 
(mmHg) SO 15 16 16 10 12 
(X mean, SD standard deviation, BMI - Body Mass Index, SBP - Systolic Blood 
Pressure; DBP = Diastolic Blood Pressure; Means v..1th the same symbol differ significantly 
from each other v..1th a p < 0.05 - paired t-tests) 
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4.3.1.2 Changes in lipid profiles ofthe placebo group (see Table 4.61 
Compared to baseline 2, no changes were measured in any of the 
lipid measurements. 
Table 4.6 Changes in the lipid profiles of the placebo group: 
VARIABLE OayO OayS Oay22 Oay36 Oay43 
TC X 4.23 4.36 4.29 4.30 4.42 
(mmoI/L) SO 0.98 0.71 0.97 0.49 0.88 
TG X 1.29 1.24 1.12 1.27 1.18 
(mmoI/L) SO 0.39 0.69 0.47 0.41 0.75 
HOL-C X 1.26 1.18 1.34 1.20 1.43 
(mmoI/L) SO 0.24 0.23 0.27 0.23 0.31 
LOL-C X 2.22 2.47 2.42 2.45 2.54 
(mmoI/L) SO 0.74 0.80 0.76 0.50 0.78 
%HOL-C X 32 .2 28.3 32.3 30.50 32.70 
(%) SO 6.30 8.00 7.10 6.10 9.10 
NEFA X 3.33 3.54 3.68 4.92 3.65 
(mmoI/L) SO 1.99 1.47 1.99 1.90 2.43 
(X - mean , SD - standard deviation , means Wlth the same symbol differ slgmficantly from 
each other with a p < 0.05 - paired t-tests ; TC = serum-Total Cholesterol ; TG = serum-
Triglycerides ; HDL-C = serum-High-Density Lipoprotein Cholesterol ; LDL-C = serum-Low-
Density Lipoprotein Cholesterol ; %HDL-C = HDL-CrrC • 100 ; NEFA = Non-Esterified Fatty 
Acids) 
4_3.1 .3 Changes in the glycometabolic indicators of the placebo group 
(see Table 4.71 
No Significant differences in any of the glycometabolic parameters 
of the placebo group were measured between any of the visits. The 
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measured decrease in serum-insulin levels from day 8 (baseline 2) 
to day 22 was not significant. 
Table 4.7 Changes in glycometabolic indicators of the placebo group 
VARIABLE DayO DayS Day 22 Day 36 Day 43 
Glucose X 5.08 5.65 5.12 5.15 5.52 
(mmoIlL) SD 0.57 1.16 0.93 1.21 1.07 
Insulin X 8.30 10.10 21.60 9.10 14.5 
(1lIUlmL) SD 8.90 14.90 20.70 15.30 9.70 
(X - mean, SO - standard deviation, means Wlth the same symbol differ significantly from 
each other with a p < 0.05 - paired t-tests) 
4.3.1.4 Changes in other metabolic variables of the placebo group 
(see Table 4.S) 
None of the other measured metabolic variables in the placebo 
group showed any significant change from the baseline to the end 
of the supplementation phase. 
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Table 4.8 Changes in other metabolic variables of the placebo group 
VARIABLE OayO Oay8 Oay22 Oay36 Oay43 
TP X 76.9 79.8 77.5 77.0 79.7 
(g/L) SO 4.7 3.4 6.6 4.4 4.9 
Albumin X 43.9 45.1 43.9 43.9 45.8 
(g/L) SO 2.1 2.8 3.4 2.3 1.7 
TP/Albumin X 1.8 1.8 1.8 1.8 1.7 
SO 0.1 0.1 0.1 0.1 0.1 
WBC X 6.31 5.78 5.05 5.29 5.73 
(x10l/IJL) SO 2.11 1.51 1.32 1.31 1.70 
RBC X 5.25 5.05 4.97 5.01 5.21 
(x10l/IJL) SO 0.46 0.46 0.53 0.43 0.63 
Haemoglobin X 16.1 15.2 14.9 15.8 15.9 
(g/dL) SO 1.1 0.9 1.2 1.1 1.1 
Fibrinogen X 2.82 3.53 2.88 2.68 2.92 
(g/L) SO 0.9 1.19 0.69 0.84 1.29 
Albumin/ X 17.06 16.69 16.15 18.81 19.23 
Fibrinogen SO 4.87 5.27 4.36 7.6 7.22 
(X - mean, so - standard deviation; Means Wlth the same symbol differ significantly from 
each other with a p < 0.05 - paired t-tests; TP = serum-Total Protein WBC = White Blood 
Count; RBC = Red Blood Count) 
4.3.2 The acetate/propionate/butyrate Group 
4.3.2.1 Changes in anthropometrical measurements of the 
acetate/propionate/butyrate-supplement group (See Table 4.9) 
No significant differences in any of the anthropometrical variables 
were measured after supplementation with a combination of 
acetate, propionate and butyrate. 
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Table 4.9 Changes in the anthropometrical measurements of the 
acetate/propionate/butyrate-supplement group 
VARIABLE Day 0 Day 8 Day 22 Day 36 Day 43 
Height X 1.69 
(cm) SO 0.10 
Weight X 65.1 66.1 65.6 65.7 66.6 
(kg) SO 7.4 8.2 8.1 7.8 7.4 
BMI X 22.5 22.9 22 .8 22.8 23.0 
(kg/m2) SO 1.9 2.1 2.1 2.1 1.9 
Waist X 75.5 76.4 75.9 76.5 75.6 
(cm) SO 5.2 5.1 5.5 4.9 4.8 
Hip X 95.5 96.5 96.2 96.4 96.0 
(cm) SO 4.4 5.1 5.1 4.7 4.8 
SBP X 120 116 117 116 118 
(mmHg) SO 10 12 7 8 8 
OBP X 80 81 79 79 83 
(mmHg) SO 9 9 7 8 9 
(X - mean, SO - standard deviation, means 'Mth the same symbol differ significantly from 
each other vvith a p < 0.05 - paired t-tests; BMI = Body Mass Index; SBP = SystOliC Blood 
Pressure; DBP = Diastolic Blood Pressure) 
4.3.2.2 Changes in the lipid profiles of the acetate/propionate butvrate-
supplement group (see Table 4.10) 
The acetate/propionate/butyrate-supplement caused a decrease in 
serum-TC from 4.95 ± 0.81 mmol/L to 4.57 ± 0.87 mmol/L (p=0.088) 
after 4 weeks of supplementation. However, this decrease was not 
significant. A significant decrease in serum LDL-C was measured 
from baseline to the end of the supplementation phase (from 3.10 ± 
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0.78 mmol/L to 2.61 ± 0.94 mmol/L; p =0.001). There was also a 
significant increase in the %HDL-C after the four weeks of 
supplementation (p=0 .017). 
It is interesting to note the expected significant decrease in NEFA 
levels from day 8 (baseline 2) to the end of the supplementation 
phase (from 0.385 ± 0.185 mmol/L to 0.287 ± 0.146 mmollL; p = 
0.020) . No other significant changes in any of the lipid variables in 
this group were observed. 
Table 4.10 Changes in the lipid profiles of the acetate/propionate/butyrate-
supplement group 
VARIABLE OayO Oay8 Oay 22 Oay36 Oay43 
TC X 4.70 4.95 4.96 4.57 4.74 
(mmoI/L) SO 0.75 0.81 1.24 0.87 0.90 
TG X 1.04 1.16 1.07 1.26 1.04 
(mmoI/L) SO 0.39 0.53 0.31 0.56 0.51 
HOL-C X 1.56 1.27 1.66 1.46 1.69 
(mmoI/L) SO 0.65 0.28 0.70 0.66 0.83 
LOL-C X 2.39 3.10* 2.91 2.61 * 2.61 
(mmoI/L) SO 0.85 0.78 1.27 0.94 0.94 
%HOL-C X 34.90 26.30* 33.50 32.30* 34.90 
(%) SO 11 .90 6.50 13.40 12.40 14.00 
NEFA X 3.60* 3.58# 3.83 2.87*# 3.10 
(mmoI/L) SO 1.90 1.85 2.18 1.46 1.70 
(X - mean , SO - standard deviation , Means With the same symbol differ slgmflcantly from 
each other with a p < 0.05 - paired t-tests ; TC = serum-Total Cholesterol ; TG = serum-
Triglycerides ; HDL-C = serum-High-Density Lipoprotein Cholesterol ; LDL-C = serum-Low-
Density Lipoprotein Cholesterol ; %HDL-C = HDL-CfTC • 100 ; NEFA = Non-Esterified Fatty 
Acids) 
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4.3.2.3 Changes in the glycometabolic indicators of the 
acetate/propionate/butyrate-supplement group (see Table 4.111 
The mean fasting serum-glucose levels decreased significantly 
during supplementation (from day 8 to day 36; p=0.028). The 
circulating serum-insulin levels also showed a concomitant 
decrease during the supplementation (p<0.001). 
Table 4.11 Changes in the glycometabolic indicators of the 
acetate/propionate/butyrate-supplement group 
VARIABLE OayO OayS Oay22 Oay36 Oay43 
Glucose X 5.43 5.41· 5.46 4.96· 5.72 
(mmoI/L) SO 1.37 0.52 0.96 0.85 0.73 
Insulin X 6.70 5.80· 10.90 1.70· 15.80 
(1lIUlmL) SO 3.60 0.77 4.90 0.36 9.90 
(X - mean, SO - standard deViation, Means ",th the same symbol differ Significantly from , 
each other v.ith a p < 0.05 - paired t-tests 
4.3.2.4 Changes in the other metabolic variables of the 
acetate/propionate/butyrate-supplement group (See Table 4.121 
Both the serum-TP (from 81.1 ± 6.2 gIL at day 8 to 75.9 ±8.4 gIL at 
day 36; p=0.001) and the serum-albumin levels (from 45.3 ± 2.5 gIL 
to 43.3 ± 2.9 gIL; p~0.020) of this subject group decreased 
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significantly from both baselines to the end of the supplementation 
period. However, these values remained within the normal range. 
There were no significant changes in any of the blood cell counts 
during the study. 
Table 4.12 Changes in other metabolic variables of the 
acetate/propionatelbutyrate-supplement group 
VARIABLE OayO OayS Oay 22 Oay36 Oay43 
TP X 81 .90* 81.10# 79.70 75.90*# 78.20 
(gIL) 50 6.50 6.20 6.40 8.40 5.20 
Albumin X 46.80* 45.30# 44.70 43.80*# 45.40 
(gIL) 50 4.70 4.40 3.90 3.10 2.40 
TP/Albumin X 1.87* 1.79# 1.79 1.73*# 1.72 
50 0.49 0.11 0.09 0.14 0.12 
WBC X 5.96 5.77 5.89 5.88 5.65 
(x103/I1L) 50 2.47 1.42 1.30 1.63 1.43 
RBC X 5.33 5.22 5.17 5.32 5.23 
(x103/I1L) 50 0.65 0.63 0.49 0.54 0.55 
Haemoglobin X 16.2* 16.1 15.5 15.7* 15.6 
(g/dL) 50 1.2 1.9 1.3 1.2 1.5 
Fibrinogen X 2.73 2.98 2.58 2.94 2.60 
(giL) 50 0.68 0.95 0.61 0.97 0.79 
Albuminl X 17.8 17.4 17.9 16.8 20.3 
Fibrinogen 50 5.7 5.9 3.8 6.5 8.9 
(X - mean, SO - standard deviation, means With the same symbol differ significantly from 
each other with a p < 0.05 - paired t-tests; TP = serum·Total Protein; WBC = White Blood 
Count RBC = Red Blood Count) 
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4.3.3 The acetate/propionate Group 
4.3.3.1 Changes in the anthropometrical measurements of the 
acetate/propionate-supplement group (See Table 4.13) 
No significant changes were observed in any of the 
anthropometrical measurements of the acetate/propionate-
supplement group over the duration of the study. 
Table 4.13 Changes in anthropometrical measurements of the 
acetate/propionate supplement group 
VARIABLE OayO OayS Oay 22 Oay36 Oay43 
Height X 170.00 
(cm) SO 0.10 
Weight X 65.70 66.40 67.20 66.50 67.60 
(kg) SO 8.40 8.50 8.50 8.80 7.70 
BMI X 22.70 22.90 23.10 22.90 23.10 
(kg/m2) SO 2.30 2.30 2.50 2.30 2.10 
Waist X 77.50 77.00 76.70 76.40 78.50 
(cm) SO 6.60 7.10 9.00 7.20 7.20 
Hip X 95.00 94.40 94.10 94.40 95.70 
(cm) SO 4.30 4.00 8.10 4.30 4.80 
SBP X 115 115 118 116 116 
(mmHg) SO 7 9 9 8 6 
OBP X 81 80 80 82 81 
(mmHg) SO 8 8 10 6 6 
-(X - mean, SD - standard deViation; means With the same symbol differ significantly from 
each other with a p < 0.05 - paired t-tests; BMI = Body Mass Index; SBP = Systolic Blood 
Pressure; DBP = Diastolic Blood Pressure 
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4.3.3 The acetate/propionate Group 
4.3.3.1 Changes in the anthropometrical measurements of the 
acetate/propionate-supplement group (See Table 4.1 3) 
No significant changes were observed in any of the 
anthropometrical measurements of the acetate/propionate-
supplement group over the duration of the study. 
Table 4.13 Changes in anthropometrical measurements of the 
acetate/propionate supplement group 
VARIABLE OayO Oay8 Oay 22 Oay36 Oay43 
Height X 170.00 
(em) SO 0.10 
Weight X 65.70 66.40 67.20 66.50 67.60 
(kg) SO 8.40 8.50 8.50 8.80 7.70 
8MI X 22.70 22.90 23.10 22.90 23.10 
(kg/m2) SO 2.30 2.30 2.50 2.30 2.10 
Waist X 77.50 77.00 76.70 76.40 78.50 
(em) SO 6.60 7.10 9.00 7.20 7.20 
Hip X 95.00 94.40 94.10 94.40 95.70 
(em) SO 4.30 4.00 8.10 4.30 4.80 
SBP X 115 115 118 116 116 
(mmHg) SO 7 9 9 8 6 
OBP X 81 80 80 82 81 
(mmHg) SO 8 8 10 6 6 
-(X - mean, SD - standard deViation, means With the same symbol differ significantly from 
each other with a p < 0.05 - paired t-tests; BMI = Body Mass Index; SBP = Systolic Blood 
Pressure; DBP = Diastolic Blood Pressure 
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4.3.3.2 Changes in the lipid profiles of the acetate/propionate-
supplement group (See Table 4.14) 
There was no measured change in the serum-TC levels of this 
group from day 8 (baseline) to the end of supplementation. It is 
interesting to note the significant (p=0.044) increase in HDL-C 
levels from 1.21 ± 0.24 mmollL ± to 1.35 ± 0.34 mmollL from day 8 
(baseline 2) to the end of the supplementation. Furthermore, there 
was an expected significant decrease in the NEFA concentration of 
this group after supplementation with the acetate/propionate mixture 
(p=0.023). 
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Table 4.14 Changes in the lipid profiles of the acetate/propionate 
supplement group 
VARIABLE OayO OayS Oay22 Oay36 Oay43 
TC X 4.37 4.14 4.82 4.25 3.92 
(mmol/L) SO 0.96 0.81 1.00 1.77 0.80 
TG X 1.05 1.01 1.10 109 0.98 
(mmol/L) SO OA 0.39 OA2 0.36 0.27 
HOL-C X 1.39 1.21* 1.37 1.35* 1.37 
(mmol/L) SO 0.36 0.24 0.32 0.34 0.31 
LOL-C X 2.43 2.37 2.37 2.31 2.10 
(mmol/L) SO 0.90 0.58 0.32 0.71 0.71 
%HOL-C X 33.70 30.56 30.10 33.53 35.80 
(%) SO 9AO 6.14 7.90 6.38 8.70 
NEFA X 5.01* 5.02# 4.06 4.14*# 2A3 
(mmol/L) SO 2.23 1.72 2.38 3A3 1.18 
(X - mean, SD - standard deviatIOn, means Wlth the same symbol differ significantly from 
each other with a p < 0.05 - paired t-tests ; TC = serum-Total Cholesterol ; TG = serum-
Triglycerides ; HDL-C = serum-High-Density Lipoprotein Cholesterol ; LDL-C = serum-Low-
Density Lipcprotein Cholesterol ; %HDL-C = HDL-CITC * 100 ; NEFA = Non-Esterified Fatty 
Acids) 
4. 3.3.3 :!:C~h!!!a!!nHge!:;s!!..-_!!in.!....----"g~I'-I:v.!<.co~m~e~ta!!..!b~o!.!l~ic,-----!i!!n~d~ic!!!a~to~rs..2..._.!oo2.f_-.!o!th~e 
acetate/propionate-supplement group (See Table 4.151 
The fasting serum-glucose levels of this group decreased 
significantly from baseline 2 to the end of supplementation (from 
6.65 ± 0.98 mmollL at baseline 2 to 5.65 ± 0.24 mmollL, p=0.001). 
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Table 4.15 Changes in glycometabolic indicators of the acetate/propionate-
supplement group 
VARIABLE DayO Day8 Day 22 Day 36 Day 43 
Glucose X 5.87 6.65' 5.77 5.65' 5.03 
(mmoI/L) so 0.60 0.98 0.94 0.42 0.53 
Insulin X 7.90 12.62 7.10 14.01 13.80 
(1·IIU1mL) SD 4.60 22.61 5.50 24.83 9.70 
(X - mean, SO - standard devlallon, means WIth the same symbol differ significantly from 
each other with a p < 0.05 - paired t-tests) 
4. 3.3.4 .:::C"-,h!Oa,-,ng",e~s"----,o,-,f __ o".to:.h."e"-r_-,m"-""et,,a,-,,b,,,o,,,1 i"'c_--"'va",r"'ia",b"'l.::.es"----'o"'f_->!th=e 
acetate/propionate-supplement group (See Table 4.161 
Serum-albumin levels increased significantly from day 8 to the end 
of supplementation (p=0.005). A significant decrease from baseline 
(both baseline 1 and 2) to the end of the experimental phase in the 
ratio of TP to Albumin was therefore also observed (p=0.006). The 
mean Red Blood Cell Count of this group of subjects also increased 
significantly from 5.05 ± 0.57 X 1 03/~L at day 8, to 5.24 ± 0.6 x 
1 03/~L at the end of supplementation (p=0.050). 
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Table 4.16 Other metabolic variables of the acetate/propionate supplement 
group 
VARIABLE 
I 
OayO DayS Day 22 Day 36 Day 43 
TP X 82.10 78.90 79.90 77.80 77.40 
(g/L) SO 6.30 6.10 7.40 9.50 8.10 
Albumin X 44.80 43.90* 44.70 46.46* 43.50 
(g/L) SO 3.20 2.50 3.90 3.30 2.40 
TP/Albumin X 1.84* 1.80# 1.79 1.74*# 1.78 
SO 0.20 0.16 0.14 0.18 0.19 
wac X 5.65 5.43 6.17 5.11 5.41 
(x103/IJL) SO 1.57 1.6 2.14 1.58 1.69 
RBC X 4.91* 5.05# 5.11 5.24# 5.16 
(x103/IJL) SO 0.38 0.57 0.50 0.60 0.77 
Haemoglobin X 15.5 15.9 16.1 16.2 15.8 
(g/dL) SO 0.9 1.3 1.6 1.4 1.7 
Fibrinogen X 2.58 3.36 3.05 2.85 2.72 
(giL) SO 0.55 1.55 1.18 0.84 0.81 
Albuminl X 18.0 15.6 17.0 16.5 16.2 
Fibrinogen SO 3.7 6.2 4.9 4.7 5.0 
(X - mean, SD - standard deviation, means WIth the same symbol differ significantly from 
each other with a p < 0.05 - paired t·tests; TP = serum·Total Protein ; WBC = White Blood 
Count; RBC = Red Blood Count) 
4.4 A COMPARISON BETWEEN THE EFFECTS ON THE 
DIFFERENT SUPPLEMENT GROUPS (See table 4.16) 
The comparisons between the changes from baseline to the end of 
supplementation within ..the different variables between the three 
different supplement groups are presented in Table 4.6. Only the 
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most important differences between changes within the different 
supplementation groups relevant to this study will be highlighted in 
this section. 
There was a small increase in 8MI of the placebo group from 
baseline to the end of supplementation, that differed significantly 
from the change in 8MI in both the acetate/propionate/butyrate and 
the acetate/ propionate supplemented groups. 
The increase in serum-TC levels within the acetate/propionate 
supplemented group from the baseline to the end of 
supplementation was significantly greater when compared to the 
decrease in serum-TC levels of the acetate/propionate/butyrate 
supplemented group for the same time period. 
The increase in HDL-C levels and O/OHDL-C from baseline to end of 
supplementation of both the acetate/propionate/butyrate and the 
acetate/propionate supplemented groups differed significantly from 
the change in HDL-C levels within the placebo group for the same 
period of time. However, the increase in the O/OHDL-C in the 
acetate/propionatelbutyrate supplemented group was significantly 
greater when compared to the increase in O/OHDL-C in the 
acetate/propionate supplemented group. 
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The decrease in LDL-C levels of the acetate/propionate/butyrate 
supplemented group during the experimental phase was 
significantly greater when compared to the change in LDL-C levels 
in both the placebo and the acetate/propionate supplemented 
groups. 
The measured decrease in NEFA levels of both the experimental 
groups differed significantly from the increase in NEFA levels of the 
placebo group during the experimental phase of the study. 
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Table 4.17 Comparisons between mean changes in measured variables 
from day 8 to the end of supplementation (day 36) within the three 
different supplement groups 
Placebo Acetate!Propionate! Acetatel 
VARIABLE Supplement Butyrate Propionate 
Supplement Supplement 
Weight (kg) 0.0 -0.4 0.1 
BMI (kg/m2 ) 0.2 -0.1* 0.0# 
Waist (cm) -1.80 0.10 -0.60 
Hip (cm) 0.60 0.10* 0.00 
SBP (mmHg) -8 0 1 
DBP (mmHg) -4 -2 2 
TC (mmoI/L) -0.01 -0.38 0.11# 
TG (mmoIlL) 0.00 0.10 0.08* 
HDL-C (mmoI/L) 0.00 0.19* 0.14* 
LDL-C (mmoI/L) -0.00 -0.49* -0.06# 
%HDL-C 2.2 6.0* 3.0*# 
NEFA (mmoI/L) 1.38 -0.71* -0.88* 
Glucose (mmoI/L) -0.50 -0.45 -1.00 
Insulin (1lIU/mL) -1.00 -4.10 1.39 
TP (gIL) -2.8 -5.2* -1.1*# 
Albumin (gIL) -1.2 -1.5 2.6*# 
TP/Albumin 0.00 -0.06 -0.06 
WBC (x103/IlL) -0.49 0.11* -0.32 
RBC (x103/IlL) -0.04 0.10* 0.19* 
Haemoglobin.(g/dL) 0.6 -0.4 0.3 
Fibrinogen.(g/dL) -0.85 -0.04 -0.51 
Albumin/Fibrinogen 2.1 -0.6 0.9# 
* mean changes differ significantly from the mean changes within the placebo group 
(p<O.05); #mean changes differ significantly from the mean changes within the 
acetate/propionate/butyrate supplement group (p<O.05). A negative (-) prefix 
denotes a decrease in measurement 
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4.5 SUMMARY 
The subject group used in this study was of a very homogenous 
nature due to the strict indusion and exclusion criteria that were 
adhered to. All the subjects were male, and between the ages of 18 
and 45 years. The study group followed exactly the same diet that 
was compiled by a registered dietician. No overweight or obese 
subjects were included in this study. All measured anthropometric 
characteristics and blood pressure mirrored a healthy physical 
status. The serum-TC of the group as a whole was 4.46 ±O.84 
mmol/L with the serum-HDL-C and -LDL-C, 1.24±O.28 mmol/L and 
2.67±O.78 mmol/L, respectively. None of the other measured 
metabolic variables were abnormal or indicative of any present 
abnormalities. 
Blood was analysed after two and four weeks of supplementation 
with two different combinations of short-chain fatty acids and a 
placebo, in order to assess whether these fatty acids had had any 
metabolic effects that could be to the benefit of the subjects. The 
effect of the different supplements will mainly focus on changes in 
any of the measured lipid profiles. 
No significant changes were measured in any of the lipid fractions, 
including the total cholesterol of the placebo group. The 
acetate/propionate/butyrate supplement caused a decrease, albeit 
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not significant, in serum-TC from 4.95 ± 0.81 to 4.57 mmol/L ± 0.87 
and HDL-C from 1.27 ± 0.28 to 1.46 ± 0.66 mmol/L. These two 
effects are mentioned because they are directly linked to the 
%HDL-C which increased significantly from 26.3 ± 6.5% to 32 .3 ± 
12.4%. The serum-LDL also decreased significantly from 3.10 ± 
0.78 to 2.61 ± 0.94 mmol/L. 
The combination of acetate and propionate caused no changes in 
the serum-TC levels of the subjects. However, a small significant 
increase in the serum-HDL (from 1.21 ± 0.24 to 1.35 ± 0.34 mmol/L) 
was measured. The supplement had no effect on the serum-LDL-C 
levels. 
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CHAPTERS 
DISCUSSION 
5.1 INTRODUCTION 
The main aim of this study was to detenmine the possible effect of 
different combinations of SCFAs on the lipid profiles of westernised 
black men. By doing so, it is believed that the attributable risk 
contributed by high serum-cholesterol levels in this population group 
could be decreased. Two different combinations of SCFAs and a 
placebo supplement were used in order to determine whether the 
specific combinations of SCFAs would have any effect on the lipid 
profiles of the respective study groups. Other more general metabolic 
indicators, as well as the anthropometric status and the blood pressure 
of the subjects were also monitored. 
In this chapter, the main changes from the reference baseline (Day 8) 
to the end of the supplementation phase (Day 36) in the three different 
supplementation groups will be discussed. The results of this study will 
also be compared with the data of other similar studies. 
5.2 BASELINE CHARACTERISTICS OF THE GROUP AS A WHOLE 
5.2.1 Demographic characteristics of the study group as a whole 
The study group was very homogenous. This could mainly be ascribed 
to the strict inclusion criteria adhered to during the recruitment of 
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volunteers. Recruited subjects had healthy physical dimensions (body 
weight, etc.). All subjects were living on the same military base, where 
they received the same controlled westernised diet at a central mess 
hall, and also participated in exactly the same physical activities. In 
addition, subjects with a history of previous or current cardiovascular 
events, diabetes, hyper- or hypotension were excluded from the study. 
Subjects with a history of familial diseases were also excluded from the 
study. It is therefore evident that the group was perfect to use for 
intervention purposes, due to the strict control that could be assured 
throughout the study. 
5.2.2 Anthropometric measurements of the study group as a whole 
The Body Mass Index (BMI) of the group as a whole fell within the 
estimated limits of the normal reference range for healthy adult males 
(18.5 to 24.9 kg/m2 , Tietz 1998). All other anthropometric dimensions 
of the group as a whole supported this outcome. 
5.2.3 Lipid profiles of the study group as a whole 
Serum total-cholesterol (TC) levels are directly, and high-density 
lipoprotein cholesterol (HDL-C) levels inversely, related to CHD 
(Kannel and Wilson, 1995). Subjects with healthy lipid profiles were 
recruited for this study. However, individuals with cholesterol levels in 
the higher range of the normal were recruited in order to ensure that it 
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would still be possible to detect the hypothesised beneficial cholesterol-
lowering effect of the SCFA supplements. Serum lipid fractions were 
measured to quantify the possible effects of the different combinations 
of supplements. 
Mollentze et al. (1995) reported mean serum-TC levels of between 4.7 
± 1.2 mmol/L for black men in the age category 25-34 years living in 
Mangaung. Most of our subjects were from Mangaung. The authors 
also reported that the number of subjects in the moderate-risk 
hypercholesterolaemic category in this population is disturbing. An 
outstanding feature was that subjects in the younger age groups had a 
higher prevalence of hypercholesterolaemia. This could possibly 
reflect the more powerful impact of urbanisation on the younger 
generation, who may be adopting a Westem diet to a greater extent 
than their elders (Mollentze et al. , 1995). However, serum-TC on its 
own is not an accurate predictor of cardiovascular events, and should 
be evaluated together with the three other main serum-lipid fractions; 
namely High-Density Lipoprotein Cholesterol (HDL-C), Low-Density 
Lipoprotein Cholesterol (LDL-C) and Triglycerides (TG). The 
measured concentrations of these combined fractions predicted that 
the individuals used for this study were not at immediate high risk of 
cardiovascular events (Steyn et at, 1991 ; Seed at et al., 1992; 
Mollentze et al., 1995; Slabber et at, 1997). However, the lipid profiles 
do suggest that a current improvement in cardiovascular risk profiles is 
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possible, and that it would be to the benefit of the subjects' health to 
sustain such an improvement when they grow older. 
5.2.4 Glycometabolic indicators of the study group as a whole 
The fasting serum-glucose and insulin levels of the subject group as a 
whole did not reflect the presence of any apparent glycometabolic 
disorders. Glucose levels of healthy individuals can fluctuate between 
4.6 - 6.4 mmol/L (Painter et aI., 1999). High glucose levels were 
reported for urban black populations in Durban, where the prevalence 
towards higher blood glucose levels (>7.9 mmol/L) is high (Seed at et 
al., 1992). Fasting serum-glucose levels of between 4.7 ± 0.3 mmol/L 
were reported in a previous study conducted in our own laboratory 
using the same population-source (De Wet, 1999). Insulin levels of a 
healthy individual should vary between 0-17 ~IU/mL depending on the 
time of day and the state of fasting (Painter et al ., 1999). 
Epidemiological studies report that insulin is also a risk factor for CHD 
(Kannel and Wilson , 1995). Furthermore, insulin is essential for the 
physiological regulation of HDL-C metabolism (Wolever et al., 2002). 
It is suggested that the high level of physical activity, age and absence 
of obesity may benefit the subjects used in this study in terms of 
glycometabolic control. 
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5.2.5 Other metabolic variables of the study group as a whole 
A comprehensive profile of metabolic markers, all of which reflect the 
general health status of the individual, was analysed. Not all of these 
markers will be discussed, and only those of interest highlighted. 
Albumin is acknowledged to be an important indicator of nutritional 
status and longevity (Carlson, 2004). The serum-albumin levels of this 
group fell within the normal reference range of between 35-52 gIL for 
healthy adult males (Painter et al., 1999), and it could therefore be said 
that the study population was apparently healthy. This claim is also 
supported by the other measured variables. The blood counts of both 
the Red and White Blood Cells fell within the normal range of 4.5-6.5 x 
1 03/~IU and 4-11 x 1 03/~IU, respectively (Davidson 1991). 
Plasma fibrinogen used as an acute phase marker showed that no 
infection or disease states which trigger an acute phase response were 
present throughout the study (Davidson 1991). The concentration of 
this protein fell within the normal reference range given for the specific 
population group (34-52 gIL; Painter et al., 1999). Plasma fibrinogen is 
also an accepted risk marker for cardiovascular events (Painter et al., 
1999), however, it will not be discussed as such. 
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5.3 CHANGES MEASURED DURING THE INTERVENTION PERIOD 
5.3.1 Introduction 
Other studies showed that the clinical effects of SCFA administration 
may be influenced by the method of administration (oral, rectal or 
intravenous). The capsules used for this study were coated with a thin 
layer of polymer. This prevented the acidity of the stomach from 
dissolving the capsules, and allowed enzymes in the small gut to digest 
them. This ensured that maximum distribution of the supplements took 
place within the colon, resembling the SCFA distribution when dietary 
fibre is fermented. Also, it seems that the frequency and concentration 
of the SCFA administered plays a significant role in the clinical 
manifestations of effects. Intravenous SCFA injections may cause 
acute acidosis at high concentrations, while rectal infusions of SCFAs 
may be influenced by the depth of administration. Capsulated SCFA 
supplements may therefore be a much safer and more trustworthy 
method of administration when compared to any other. 
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5.3.2 The placebo group 
5.3.2.1 Changes in the anthropometrical measurements of the placebo 
group 
No significant changes in any of the anthropometric variables within the 
placebo group were measured during the study. It was not expected 
that the placebo supplement should cause any changes to the 
anthropometrical measurements of this group of individuals. 
5.3.2.2 Changes in the lipid profiles ofthe placebo group 
Serum-cholesterol levels of the placebo group did not show any 
changes from baseline to the end of the experimental phase. No other 
changes were measured in any of the cholesterol fractions. 
5.3.2.3 Changes in glycometabolic indicators of the placebo group. 
No significant differences in any of the glycometabolic parameters of 
the placebo group were measured between the visits. It was not 
expected that the placebo should introduce any glycometabolic 
changes in the study group 
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5.3.2.3 Changes in other metabolic varia bles of the placebo group 
None of the metabolic variables within the placebo group showed any 
significant changes from baseline to the end of the study. 
5.3.3 The acetate/ propionate/ butyrate group 
5.3.3.1 Changes in the anthropometrical measurements of the 
acetate/propionate/butyrate-supplement group 
No significant differences in any of the anthropometrical variables were 
measured. The tendency towards a decrease in group two of the BMI 
was not statistically significant. 
5.3.3.2 Changes in the lipid profiles of the acetate/propionate/butyrate-
supplement group 
The acetate/propionate/butyrate-supplement caused a non-significant 
decrease in the serum TC of apprOximately 8% after four weeks of 
supplementation. This difference, however, is non-significant in 
statistical terms. In contrast, the serum-LDL-C levels significantly 
decreased (-16%) during the same period. It is evident that the small 
decrease in TC may be due to the decrease in LDL-C levels. 
Expressed as a fraction (percentage) of the TC, LDL-C decreased from 
64% (day8) to 57% (day 36). The combination of fatty acids also 
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caused a significant increase in %HDL-C levels. This increase is 
beneficial and may be exploited in future studies. 
Numerous previous studies performed on humans and animals have 
shown a definite relation between propionate and acetate, and 
cholesterol metabolism. It is known that both acetate and propionate 
influence cholesterol synthesis (Chen et aI., 1984; Nishina and 
Freeland, 1990; Wright et aI., 1990). 
Consumption of propionate reduces serum cholesterol in both animal 
and human models (Thacher et aI., 1981 ; IIlman et al., 1988; Stephan 
1994). However, very little information is available where both the 
short-chain fatty acids acetate and propionate were given in 
combination. 
The specific effect of acetate intake on cholesterol metabolism is 
controversial. Wolever et al. (1989) suggest that acetate may reduce 
cholesterol synthesis by reducing the circulating free fatty acid (NEFA) 
concentration. NEFA concentration in this group decreased 
significantly during supplementation. A decrease in NEFA levels is 
associated with an increase in short-chain fatty acid concentrations and 
therefore serves as an indication that the SCFAs within the 
supplements were absorbed, and reached the peripheral circulation 
(Scheppach et al., 1988; Ak-anji et al., 1991 ; Veldman , 1996). 
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Acetate derived from colonic fermentation could also be a substrate for 
hepatic lipid synthesis. The first step in acetate metabolism is its 
activation to acetyl-CoA by the enzyme acetyl-CoA synthetase, which 
is variably distributed in the cytosol and mitochondria of many tissues 
(Brockman, 1982; Scheppach et al., 1988). Acetyl-CoA, in turn, is the 
primary substrate for de novo cholesterol and triglyceride synthesis 
(McBurney and Thompson 1989; McBurney et al., 1988). However, 
addition of propionate to acetate supplements is reported to inhibit the 
incorporation of acetate into plasma triglycerides (Wolever et al., 
1995). 
Very little information is available on the effect of butyrate on 
cholesterol metabolism in human subjects (Topping and Pant, 1995). 
5.3.3.3 Changes in the glycometabolic Indicators of the 
acetate/propionate/butyrate-supplement group 
The combination of acetate, propionate and butyrate caused a 
statistically significant decrease in serum-glucose levels. A 
concomitant decrease in circulating insulin levels was also measured. 
This concomitant change is beneficial, and implies that the body 
requires less insulin to keep the glucose levels in circulation at a 
constant concentration. The results suggest that the supplement 
improves insulin resistance. A possible pathway to explore would be 
to investigate the possibility that the supplement increases the 
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number of insulin receptors on the surface of the cell membrane. 
These receptors, once activated by insulin , enhance the uptake of 
glucose by the cells for energy production (Meisenberg en Simmons, 
1998). In the study by De Wet (1999) in our own laboratory, a 
combination of three SCFAs (acetate, propionate and butyrate) also 
significantly decreased serum-glucose levels. Alamowitch et a!. 
(1996) on the other hand, found that the acute ileal perfusion of the 
combination of acetate, propionate and butyrate did not significantly 
reduce serum-glucose levels in human subjects. 
5.3.3.4 Other metabolic variables of the acetate/propionate/butyrate-
supplement group 
Both the serum-TP and albumin of this group showed a significant 
decrease from baseline to the end of the supplementation phase. 
Generally, a decrease in circulating albumin levels is not favourable. 
However, the decrease in the serum-TP levels were much greater 
compared to that of the albumin. The ratio of TP to albumin therefore 
decreased, which, in turn, is favourable. This change indicates that 
the fraction of the total protein comprised of albumin was greater at 
the end of the study, compared to the measured fraction at the 
reference baseline. As already mentioned, serum albumin is a 
marker for both longevity and nutritional status (Lindsey, 1996). It is 
important to note that -even after a significant decrease, the 
concentration of both total protein and serum-albumin still fell within 
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the normal reference range for healthy male adults (Painter et al. , 
1999). No published data could be found regarding any changes in 
the albumin and/or total protein levels recorded after short-chain fatty 
acid supplementation. 
A decrease in the haemoglobin levels in this group was observed. 
Veldman et al. (1997) also reported a decrease in haemoglobin 
levels after 4 weeks of supplementation with pectin (a soluble dietary 
fibre) using hypercholesterolaemic males as subjects. Similar results 
were also published by the same author after 4 weeks of 
supplementation with an enteric coated acetate supplement 
(Veldman et at, 1999). 
No other significant changes were measured in any of the other 
metabolic variables. 
5.3.4 The acetate/propionate group 
5.3.4.1 Changes in the anthropometrical measurements of the 
acetate/propionate-supplement group 
There was no significant change in any of the anthropometrical 
measurements of the acetate/ propionate supplemented group over 
the duration of the study. -
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5.3.4.2 Changes in the lipid profiles of the acetate/propionate-
supplement group 
Previous rectal infusion studies performed by Wolever et aI., (1991 
and 1995) showed that colonic acetate was incorporated into serum 
cholesterol and triglycerides, and acutely raised the concentration of 
serum lipids, and that these effects are blocked by propionate. In this 
study group (receiving a combination of acetate and propionate salts) 
a beneficial statistically significant increase of the serum HDL-C was 
observed, without any changes in the other lipid fractions. A sodium 
propionate supplement also increased HDL-C and serum-TG levels in 
a study performed by Venter et al. (1989). The authors hypothesise 
that this effect may, in part, be mediated through the effects of 
propionate on hepatic carbohydrate metabolism. 
Wolever et al. (1996) reported that the ratio of acetate to propionate 
in the peripheral serum of fasting normolidaemic males (n=62) were 
significantly related to the serum-TC (r=0.466; p= 0.0002) and LDL-C 
(r=0.384; p=0.0023). The authors also suggest that either increased 
acetate production relative to propionate concentration, or reduced 
propionate production relative to acetate concentration, increases 
cholesterol production. 
NEFA concentration in this group also decreased significantly during 
supplementation. As explained earlier, a decrease in NEFA levels is 
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associated with an increase in short-chain fatty acid concentrations 
and therefore serves as an indication that the SCFAs within the 
supplements were absorbed and had reached the peripheral 
circulation (Crouse et al., 1978; Scheppach et aI., 1988; Akanji et aI., 
1991; Veldman, 1996). 
5.3.4.3 Changes in the glycometabolic indicators of the 
acetate/propionate-supplement group 
A significant decrease in the fasting serum-glucose lEvels was 
measured from baseline to end of supplementation with a mixture of 
acetate/propionate. In contrast with the acetate/propionate and 
butyrate supplement, no change in the serum-insulin concentrations 
was measured. Akanji et al. (1991) demonstrated a rise in acetate 
production and a decrease in fasting serum-glucose levels associated 
with a high fibre diet given to diabetic subjects. It is suggested that 
the blood glucose lowering effect of soluble dietary fibres may be 
related, in part, to short-chain fatty acids (SCFAs) generated during 
their fermentation (Thacker et al., 1981). However, the physical 
characteristics of the fibre itself, plays a role as well. The expected 
effects of SCFAs on glucose metabolism are not clear-cut: Acetate 
could reduce blood glucose levels in the long-term by reducing NEFA 
concentrations (Crouse et aI., 1968), but propionate may have the 
opposite effect, being a gluconeogenic substrate in ruminants and 
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horses (Judson et al., 1968). In contradiction , Venter et al. (1989) 
found that a propionate supplement significantly decreased the 
fasting glucose levels as well as the maximum insulin increments 
during glucose tolerance tests. The authors suggest that the known 
beneficial effects of dietary fibre may in part be mediated through the 
effects of propionate on hepatic carbohydrate metabolism. 
Wolever et al. (1991) found that a rectal infusion of acetate had no 
effect on blood glucose levels. However, a rectal infusion of 
propionate caused a significant increase in the measured serum-
glucose levels in human subjects. A combination of these acids in 
the ratio of 3 parts acetate to 1 part propionate also had no effect on 
the serum-glucose levels. However, it caused a significant decrease 
in serum-insulin levels. It is important to remember that these effects 
were measured within 30 minutes after infusion of the fatty acids, 
thus excluding the effect of long-term use. A direct comparison 
between the results of this study, and those reported by Wolever et 
al. (1991), would therefore be impossible. 
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5.3.4.4 Changes in the other metabolic variables of the 
acetate/propionate-supplement group 
A significant increase in the serum-albumin concentration was 
observed from baseline to the end of the experimental 
supplementation. Albumin is a health-promoting protein and exerts 
beneficial effects within the framework of human pathology (Johnson 
et al., 1999). 
The observed statistically significant increase in the RBC count is 
clinically of no significance (Painter et al., 1999). This increase will 
not be discussed, but needs further investigation. No other changes 
in any of the measured metabolic variables were observed in this 
group. 
5.4 A COMPARISON BETWEEN THE EFFECTS OF THE DIFFERENT 
SUPPLEMENT GROUPS 
Results from this study show that there was a definite and clear 
difference in response to the different SCFA mixtures. This section 
will be used to identify these differences. In order to explain these 
differences, it will also be necessary to focus on the different contents 
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of the two experimental supplements, in order to differentiate 
between possible mechanisms involved during their metabolic 
actions. Only those differences that are of clinical significance will be 
discussed. The discussion will , furthermore, be limited to those 
markers relevant to the topic of this study. It should also be noted 
that very little literature is available on the long-term use of short-
chain fatty acids, and most comparisons would make use of available 
data obtained by means of short-term human and in vitro studies. 
Also, most studies applied either rectal infusions or intravenous 
injections of SCFAs, which differs to the encapsulated supplements 
used in this study. It is widely reported in the literature that a definite 
difference exists in response to the different routes of administration 
when supplementing humans with combinations of SCFAs (Wolever 
et al., 1995). Another characteristic that could provoke different 
physiological responses to supplementation could also be ascribed to 
the exact consistency of the SCFA salts used during the study, 
whether it is the sodium, calcium or potassium salt, or even the free 
base of the acid. Also, the specific characteristics of each salt could 
influence the bioavailability of the supplement. All these aspects are 
important to consider when comparisons are made to other published 
data, and should be kept in mind when reading the following 
paragraphs. 
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One of the supplements contained a mixture of acetate, propionate 
and butyrate in a ratio of 70% acetate, 15% propionate and 15% 
butyrate. The other supplement contained a mixture of acetate and 
propionate only, in a ratio of 50% acetate and 50% propionate. This 
implies that differences in metabolic response to the two different 
supplements could be ascribed to the following mechanism: 
• Both the ratio of acetate to propionate, as well as the absence or 
presence of butyrate, which may each evoke a different 
physiological response. 
The results from this study show that the oral consumption of acetate, 
propionate and butyrate has a definite influence on the cholesterol 
metabolism of apparently healthy male volunteers. These results are 
supported by other authors (Cummings and Madairlane, 1991). It 
has long been hypothesised that SCFAs produced during colonic 
fermentation of dietary fibre may mediate, at least in part, the serum 
cholesterol-lowering effect associated with the intake of soluble fibre 
(Wolever et al., 1996). The precise metabolic mechanism of the 
action of SCFAs in reducing plasma cholesterol concentrations, 
specifically LDL-C, is unknown (Wolever et aI., 1995). 
In previous studies, interest has focused largely on the potential 
inhibition of cholesterol synthesis by acetate and propionate (Beynen 
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et al. , 1982; IIlman et al., 1988; Wright et al. , 1990; Venter et al. , 
1990). 
It was proposed by Wolever et al., (1995) that acetate was used as a 
substrate for cholesterol synthesis and that it was inhibited by the 
presence of propionate. After an infusion of a ratio of acetate to 
propionate of 2:1 they reported that acetate was incorporated in 
cholesterol and triglycerides, and that propionate inhibited the 
incorporation of acetate into fatty acids due to the inhibition of acetyl 
-CoA. The outcome of the Wolever et al. (1995) study suggests that 
a higher intake of propionate may then have a more beneficial effect 
on the lipid profiles of human subjects. In our study the supplement 
containing acetate and propionate in a ratio of 1: 1 had a small , albeit 
favourable, effect on the lipid profiles of the subject group. The 
acetate/propionate/butyrate (in a ratio of 7: 1.5: 1.5) supplement had 
an even more favourable effect on lipid metabolism when compared 
to the acetate and propionate supplement. A small decrease in the 
TC, with a significantly greater increase in the HDL-C fraction and a 
significan~y greater decrease in the LDL-C fraction, was measured 
when compared to the acetate and propionate supplement. This 
suggests that, at least in males, either increased acetate production 
relative to propionate production, or reduced propionate production 
relative to acetate production, increases serum cholesterol 
concentrations (Wolever et al., 1996). SCFAs produced during 
fermentation do not exist in isolation, and the proportion of acetate 
produced is always greater when compared to that of propionate 
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(Mortensen et al ., 1988). The production of butyrate during the 
fermentation of dietary fibre may also have additional beneficial 
metabolic effects. However, Wolever et al. (1996) reported that there 
was no definite relationship between butyrate and lipid fractions in the 
fasting state. 
Furthermore, the clinical non-significant differences between the 
changes within the different groups could possibly be attributed to the 
short duration of the study. Wolever et al. (2002) proposed a three to 
six month adaptation period for SCFAs to show a positive relation to 
the lipid profile of Type" diabetes patients, and they concluded that it 
may take many months for the changes in serum SCFAs to produce 
significant metabolic changes; and that serum acetate was 
significantly related to the long term adaptive changes in blood lipids. 
Also, in support of this, our study show there is a tendency towards 
body weight changes, and that these changes may, in part, be related 
to the changes in the different lipid fractions. However, 4 weeks of 
supplementation may not be adequate to show this relationship, and 
therefore requires further investigation. 
122 
© Central University of Technology, Free State
CHAPTER 6 
CONCLUSION AND RECOMMENDATIONS 
6.1 INTRODUCTION 
Few relationships are as well established as that between total serum 
cholesterol levels (TC) and the risk of coronary heart disease (CHD) 
(Willet, 1998). Serum-TC as an entity is not a stand-alone prediction of 
CHD. The total serum-cholesterol level is represented by several 
subcomponents, induding the deleterious low-density lipoprotein (LDL) 
and very low density lipoprotein (VLDL) fractions, as well as the 
beneficial high-density lipoprotein (HDL) component. Furthermore, it is 
widely acknowledged that there exists a direct or indirect association 
between serum cholesterol and some lifestyle factors, especially 
dietary intake. Abundant data since World War II indicates that the 
dietary risk related to CHD is preventable. A variety of research studies 
has shown that dietary intervention could promote a healthy cholesterol 
profile. The use of soluble dietary to lower the LDL-C component of 
serum-TC in individuals with secondary hypercholesterolaemia has 
previously been published. The effect of a specific dietary component 
might therefore increase, decrease, or have no effect on the risk of 
CHD, depending on the cholesterol-specific component influenced 
(Willet, 1998). This may_ hold important therapeutic implications. 
Hopefully, results from this study will provide a foundation to 
investigate further possible ways in which the rising incidence of 
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cardiovascular disease in the Black South African population could be 
decreased or prevented. 
6.2 CONCLUSION 
This study was used to investigate the possible effect of 28 days' 
exposure to two different combinations of short-chain fatty acids 
(SCFAs) orally administered in a group of local westernised Black men. 
The concentration of SCFAs used was equivalent to that generated by 
the fermentation of 15g of mixed fibre. The specific combinations of 
SCFAs gives further insight into the metabolic changes associated with 
the production and absorption of the respective fermentation products 
of dietary fibre. 
One of the supplements contained a mixture of acetate, propionate and 
butyrate in a ratio of 70% acetate, 15% propionate and 15% butyrate. 
The other supplement contained only a mixture of acetate and 
propionate , in a ratio of 50% acetate and 50% propionate. It is 
believed that the increase of colonic acetate will have a positive effect 
on the lipid profile. Differences in metabolic response to the two 
different supplements could be ascribed to the following mechanism: 
o The ratio of acetate to propionate, as well as the absence or 
presence of butyrate which may each evoke a collaborative 
physiological response. 
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From the results it is evident that the inclusion of butyrate to the 
supplement was more beneficial in tenms of lipid-lowering effects. A 
significant decrease in LDL-C concentration , as well as a significant 
increase in the ratio of HDL-C to the total cholesterol concentration, 
compared to only a small statistically significant increase in HDL-C 
concentration itself in the acetate and propionate supplemented group, 
is indeed promising. These profile changes associated with the 
additional intake of butyrate reflects a decrease in risk for the future 
development of CHD. 
The prudent low fat, high-fibre diet is regarded as one of the few 
controllable risk factors in the prevention of degenerative diseases and 
is, therefore, also effective in controlling known coronary risk factors 
(hyperinsulinaemia, hyperlipidaemia, hypertension, obesity, etc.) as 
well as raised clotting factors (Vorster et al., 1988; Hubbard et al ., 
1994; Vorster et al. , 1997). It is evident from this study that the 
production of short-chain fatty acids as a by-product from microbial 
fenmentation, does contribute, in part, to the beneficial metabolic 
effects associated with the intake of dietary fibre. The results also 
show that the metabolic effects depend on different combinations of 
SCFAs produced, and is therefore also influenced by the intake of 
specific types of dietary fibre. However, it is very important to 
acknowledge that the use of SCFA supplements should not replace the 
intake of dietary fibre . The I'hysical characteristics of dietary fibre itself 
also contribute to its metabolic effects. It can therefore be concluded 
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that short-chain fatty acid supplements could be used to the benefit of 
those individuals suffering from lifestyle diseases; but that the most 
appropriate ratio of acetate, propionate and butyrate supplementation 
needs further research. 
6.3 RECOMMENDATIONS 
6.3.1 Further research 
This study dearly underlines the need for further investigation. More 
clinical intervention trials are required to investigate the most beneficial 
combination of SCFAs on lipid profiles in human subjects. Also, it will 
be required that different target groups suffering from lifestyle 
associated diseases with abnormal lipid profiles be investigated, such 
as individuals with insulin resistance, obese individuals, etc. 
The findings of the present study also indicate that further research is 
needed to evaluate the effect of long-term use of SCFA supplements. 
It is advisable that a period of at least 6 months of supplementation be 
used to evaluate the metabolic changes that take place, if any. 
6.3.2 Dietary recommendations and possible clinical use 
The results of this study show that the intake of SCFA supplements 
which include butyrate as ingredient have more beneficial effects on 
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the lipid profiles in westernised Black men, when compared to 
supplements that only include acetate and propionate as ingredients. 
However, effects on the total and LDL-cholesterol were not large 
enough to market it as a lipid-lowering drug. This suggests that short-
chain fatty acids may be used as a food supplement. However, the 
appropriate combination of fatty acids, and the most appropriate 
method of application , needs further investigation. 
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APPENDIX 1 
CONSENT FORM 
THE EFFECTS OF SHORT-CHAIN FATTY ACIDS ON GLYCOMETABOLIC 
CONTROL IN MEN 
DECLARA TION BY OR ON BEHALF OF THE PARTICIPANT 
I, ... '" .... ... .. ... ..... . ..... . .... ...... ... .. .... .. .. .. .... . ..... . ... ....... ........... .. . undersigned, 
of.. ............. . .. . . .. ... . ... ..... ...... ... . ... . . .... .. .... . .. ...... ... .. . .... ...... .. . ..... ............ . 
...................... . . . ........ .. . ....... .. .... . ... .. ........ . ......... .. ............ .. . ...... (address) 
Identity number: . . .................. .. . ... . ....................... . 
A I confirm that: 
l. I have been asked to participate in the above-mentioned research project, carried 
out by the Fibrinogen Unit, Technikon Free State and University of the Orange 
Free State. 
2. The information including the purpose of the study, advantages and disadvantages 
have been completely explained to me. 
3. I give my permission for the use of the results obtained in this research project for 
publication purpose, thus making other scientists aware of the findings as long as 
my anonymity is protected at all times. The information obtained will be 
confidential. 
4. It was clearly explained to me that I can refuse to participate in this study or I can 
withdraw my permission to participate at any time. If! refuse or withdraw, I will 
not be disadvantaged in any way and it will not be held against me. 
5. The information was explained to me by . ........................................ (name 
of interviewer) in ........................ (language) and I confirm that I have good 
command of this language and understood the explanations. I was also given the 
opportunity to ask questions on things I did not understand, and I can also ask 
further questions at any time during the project. 
6. No pressure was applied on me to take part in this research project. 
© Central University of Technology, Free State
B I hereby agree voluntarily to take part in this research project. 
Signed/confirmed at . .. .... . . ................ .. ... ........ . .. .. on ... .. . ... ..... . ..... ' ...... ... 200 1 
.... ............ .... .. .. (signature) 
Participant Witness 
© Central University of Technology, Free State
DECLARATION BY OR ON BEHALF OF RESEARCHER 
I , .................... . ..................................... .. ..... .... ................. , declare that: 
1. I have explained the information in this document and about the project to .. 
.. .. ......... ......... ..... ... .. ....... .. . ... (name of participant). 
2 I asked the participant to ask any questions if something was not clear. 
3 That the interview was conducted in English, Afrikaans, or ........ . ... (language) 
OR that the interview was conducted in ...... ... . . .. . . . ......... (language) with the 
help ofa translator, ....................... ... .. .. . ... . . ... .. . .. . . . . (name of translator). 
Signed/confirmed at .... . . .. .... ... .... .. . .. . .. ... ... . . . . ... . on . ... .. .. ... ... .. ... .. . . . ...... 2001 
(signature) 
Researcher or his representative Witness 
DECLARATION BY TRANSLATOR 
I , ...... .. ... . ......................................... . ........................ , declare that: 
1 I have translated the content of this document from English! Afrikaans into 
.. .. .. .. .. .. .. .. .. .. .. . (language) to .. .. .. .. .. .. .. .. .. .. . .. ... ......................... . 
(name of participant) and that I have translated the participant' s questions to the 
researcher or his/her representative as well as the answers of the latter to the 
participant. 
2 That the information that I have so translated was a correct interpretation of what 
I was asked to translate 
Signed/confirmed at .................... .. ... .... . .......... on ..... . .. .. .. .. ... . .... ...... .. 2000 
(signature) 
Translator Witness 
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Appendix 2 
TECHNIKON FREE STATE FmRINOGEN UNIT 
SCFA PROJECT: RECRUITMENT OUESTIONNAIRE 
DATE: --~/------~/------
INTERVIEWER: ______ _ 
SURNAME AND INITIALS: 
HOUSE DOCTOR: 
PATIENT: 
NAME: _______________ _ 
ADDRESS: 
SECTIONIDEPARTMENT: ________ __ 
TEL: 
------------------
AGE: __ -'years ____ months 
SMOKING HABITS: 
YES 
NO 
BODY MASS: ________ kg 
LENGTH: _____ cm 
© Central University of Technology, Free State
BLOOD PRESSURE: __ 1 __ 
ACTIVITY LEVEL: 
FAMILY mSTORY: 
MEDICAL mSTORY: 
INACTIVE 
MEDIUM ACTIVE 
ACTIVE 
CORONARY HEART DISEASE 
DIABETES MELLITUS 
HYPERCHOLESTEROLAENnA 
OTHER (specify): 
ANGINA/CORONARY HEART DIASEASE 
MYOCARDIAL INFARCTION 
STROKE 
BYPASS 
BLOOD CLOTS 
HIGH BLOOD PRESSURE 
DIABETES TYPE IIII 
F ANnLIAL CHOLESTEROL 
ANY CHRONIC DISEASES MEDICATION: 
YES 
NO 
SPECIFY: ___________ _ _ 
HOW OFTEN AND HOW MANY DAYS IN A WEEK OR WEEKEND DO YOU 
© Central University of Technology, Free State
USE ALCOHOL: 
DAILY 
WEEKLY 
MONTHLY 
OTHER: ________________ __ 
On a weekday when you drink alcohol how many drinks do you usually have? 
Per day 
Beer (how many bottles/cans 
Brandy/whisky (how many tots) 
Vodka/gin (how many tots) 
Sjerrie/sweetwine (how many 
glasses) 
Table wine (how many glases) 
Other, specify: 
On a weekend day when you drink alcohol how many drinks do you usually have? 
Per day 
Beer (how many bottles/cans 
Brandy/whisky (how many tots) 
Vodka/gin (how many tots) 
Sjerrie/sweetwine (how many 
glasses) 
Table wine (how many glases) 
Other, specify: 
BLOOD TESTS 
BLOOD CHOLESTEROL: 
FASTING GLUCOSE 
PLASMA FIDRINOGEN: 
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FOR OFFICE USE ONLY: 
SUBJECT: APPROVED REJECTED 
ASSIGNED SUBJECT NO: 
© Central University of Technology, Free State
Name: 
Force number: 
Interviewer: 
FOOD FREQUENCY QUESTIONAIRE 
Respondent number. 
QUAr\TlTATIVE FOOD FREQUENCY QUESTIONNAIRE 
I, .• L_L--.1' . 
Th:lnk you [or gmng your tunc: [0 puniclp:ut! in tillS sUI':"ey We. would like 10 rind cut If shon...:h;JlJI f:l1T) 
aCids. \\'11Ich 15 J icrment:Hion product of d!clo,0' fiber. 11:]\'C :J efrec! 'Oil blood sug:rr :.lnd-illSulin h!\'els 
111 men The: shon-<:hJin fJlry acids \\'111 be gl\·t! !1 10 you III the: farm Of:l CJPsuk. The UU'Orlllill ion 
JOQU[ your l!:JllOg hJbUS IS impOn~IIH :IS 1,1 will I~JI us If this supplemelll 1t,:.lS :lny effect on the eJung 
h:lbl\s oi people: t:!.klng II 
PkJse think cJreJi..1!l~· JboUI the (o,Jd :md drinks you h.:l\'e consumed during the P:.JS\ II months. J Will non 
~o through :l list of roods :Jnd drinks with YO Il ilnd 1 would like you \0 Iell me ' 
if you l!JI these pJI1ICUIJf roods. 
ho\\' the food IS prep:.m:d \b~ th~ 1\\I.:SS or elsl.:\\'ht:rc:) 
how lIIlIch or tit..: lood ~()II"::'Jl:II:1 litHe. am! 
ho\\ 1\l:1f\~ 11011.:5 J d:l~' yOIl C;lI n :1I1U ,r :nHI do 1101 e:1t II t,!n:r;. d:l~, ho\\ m:llly [lI1ICS:'\ \\t,!d. or:\ 
IIl011lh IL IS C:IIO::lI" 
T I,) help ~ou describe the :lIIIOIIII! or ro~cl. I \\"111 sho\\ you models or dlIT.:rclII :J1I10UIIlS or rood, ' 
Pk:J"SI: soy which model IS tht.: crOS!!st to the ,11110\1111 C::lIt!ll, or if II is slnJlkr. bct\Vun sizes or blg~cr th:1I1 
Ihe llIou..:ls Amounts must hi! reponed :1S cups tcl , t;Jblc::spoons (T). s!!rYlng spoons (SP) or 1!!:lSpOOns (I). 
TlIERE ARE NO RIGHT OR WRONG ANSWERS. 
EVIRYTHL~G YOU TELL ME IS CONFIDENTIAL 
IS THERE ANYTHING YOU WANT TO ASK NOW"! 
ARE YOU WILLING TO GO ON WITH THE QUESTIONS'! 
• ENCIRCLE ,\pPROPRL~ TE ANSWtR 
Do you rollow any lped:I1 diet'! y" (I) 
1. Di:lbeticdir.1 
2. Slilnm.ing diet 
J. Cholesterol die.t 
- ---
-I. Allergies 
--' 
S . Otller. (specify) 
• :'00 you u:se saJr in your food? y" (1) 
Nu (2) 
1'10(2) Don't kIlo\'!' (J) 
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Do you iJ~e :my diet:lT}' supplements? y" (1) NO(2) 
If yes, please specify the rype (name). how often. and how much: 
Vitruni.'ls: 
Miner:lis: 
Protein: 
Energy: 
Other: 
EATING PATTERNS: (FREQUENCY OF EATING ) 
PLEASE INDICA IT WHICH OF THE FOLLOWING BEST DESCRIBES THE EATING PATTERN YOU 
USUA LLY FO LLOW (MARK ONLY ONE), 
1. Nlore Ihim Ihree me:Jis wi th c:lIing bClwcen lIlc:Jls 
2. Three rne:Jls wi lh e:ning bc\we\! 11 IlIC:.!lS 
Three l11eJls \\"lIb 11 0 e:JllIlg. between lIlC;J!s 
.. Two tIlcJIs \\"Ilh CJIJ I1!}. between meals 
Two Illc:lls with no c;lljng. betwecn lIIe:lls 
(, One Illeal Wll h c:lIing betwccn meals 
7 Ol.le mC:1] wilh no C:JIlIlg. between 1llc;\ls 
X NIbble the whole d:ly. 110 spl.:cific llll.:;ds 
') Othe rs (pleasc spcclryl 
DO YOU [AT UHEAh:FASr: 
Rq~\l I :1rly (> .. IllIleS :1 \leck) 
$Oll1elIIllI.:S (1 • J InIlC S;] week) 
.\ Neyer 
HOW OFTEN DO YOU EAT AT THE FOLLOWING PLACES AWAY FROM HOME'! 
F:lmil~' I. Never 2. > onceJweek ). Weekly <. Monthly 5. > once/month 
, Monlhly 5. > onc#month ". Friends I. Ne\'er 2. > otu;t=/wl!!!k ) . Weekl~' 
Cafe I. NI! \'!!r 2. > ollt:dwl!l.!k J. WI!!!kly <. Monthly 5. > ollce/month . 
Restaurant, Fast food I. N!!\'t:r 2. > om:elwc..:k .1. W!!ckl y <. Monthly l . > om:c1month 
Other specify I. N!! \"t:r 2. > oncldw!!ek ) Weekly <. Monthly l . > ont:e1molllh 
Do you drink coffee with )'our meals? 
I. Yes 
• 2, No 
Ir yes, at which mc.aJs 
Breakfast I. Yes 2. No 
I:.Unch I. Yes 2. No 
Supper I. Yes 2. No 
. Snacks I. Yes 2. No 
- . 
108 
9· \ \ 
2·\.1 1 
1 
1 
2 1<2; 
26 
21 
2S 
29 
30 
~: ,. 
" 
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Do you drink tea (elcep t Rooibos) with your me~ls? 
• 1. Yes 
• 2. No 
IT yes, at which mells 
Brc::Ikfast I. Yes 2. No 
Lunch I. Yes 2. No 
Supper \. Yes 2. No 
Sn;lcli.s I. Yes 2. No 
With how m:my meals per d:J.)" do )'OU t!at meat fish, or pou!try? 
L One meal 
2. Two meals 
• J . Ail meJls 
... . None 
Do you C:J.t frcsh fruit :lnd/or YCl!ctahlcs: with the followinh! mC61Is:? 
lln:;II~r:J.s( I. Yes 2. No 
Lunch I. Yes 2 No 
Supper I. Yes 2. No 
511:.n:I'::I \. Yes 2. No 
How on en llo you u ~uully drink ulcohol? 
I. Every day 
2. 5-6 d<Jys I week 
J. 3--l days I week 
<. 1-2 d;:,ys I week 
5. Weekends 
6. Less than once a week 
7. Never 
On a wcekd.ay when )'OlJ po drink ulj:ph91 how man~' drinks do you usually hay!! ? 
per 
da\' 
Beer (how man~' boUIf;:s/c:ms) 
: Brandy/whisky (how many tots) 
Vodka/gin (bow m""y tots) 
Sjerrie/ sweetwine (bow ma~)' glasses) 
Table wi.ne (how m'aniglase~) 
Other, specify: 
.- <---
109 
~37 38 39 '" 
, 
• 
s 
s 
s 
s 
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On :I wcekend day when you tlo drink alcohol how many drinks do you usually ha"c ? 
Beer (how many bottlcs/cans) 
Br:lou)'hvhisky (how many tots) 
Vodkal~in (how many tots) 
Sjcrriel sweerwine (how many gbuscs) 
Tahle wine (how many glases) 
Olher, spedfy: 
Do you smoke? 
t . Never smoked 
, Smoked previously. but not currently 
3. Currently smoking 
per 
lIay 
If curn:ntly smo~ung, how m'any sigarettcs do )'OU smoke per lia~' ? 
Huw many cicarc[[cs did you :mlOl.:c a uay? 
Arc you a Ihoin:;-in f1ICm[H.:r ? I. Yes , No 
, 
6 , .. 
6 
6 
, 
, 
'--_'--------'176 
07B 
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SUMMARY OF FOOD FREQUENCY QUESTIONNAIRE 
FOOD CALCULATIONS 
· CODE AMOUNTlDA Y jgl 
. 
, 
, 
-
.. -
-
-.-
--
-
. --. _. 
,., 
g . • 6 
24 
J2 
""0 
""8 
56 
6. 
72 
80 
17· 
25· 
" 41 
<9. 
57· 
65-
7J. 
,., 
9-, 6 
24 
·32 
·'0 
." 
·56 
17· 
25 
3J 
41 
<9 
57 ·64 
-72 
·'0 
, 
6S 
" ,. 
g. 
' 6 
·2' 
5-32 
.... 0 
.... 8 
·56 
... 
5-72 
:)·60 
17 
2 
3J 
., 
.. 
57 
6 
7 
1· • 
9- .6 
1 
2 
3 
• 
• 
7·24 
S-32 
3-40 
' -48 
9-56 
7-6. 
5-72 
5 
6 
7 
1 
1 
"'0 
·8 
2 
9- •• 
7-24 
5-32 
33--<0 
41 ..... a 
.9-" 
57-&4 
65.72 
73-00 
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AMOUr-.'T TIMES EATEN 
FOOD DESCRIPTION USUALLY CODE AMOUNTIDAY 
EATEN Poe Poe Seldomln Per day 
week month ever 
Mai2e-mea[ porridge Sliff(pap) 3400 
Maize-meal porridge Soft (sfappap) 3399 
Maize-meal porridge Crumbly (phLrtu) 340\ 
Sour porridge Specify ratio Mabe!1a1Maize 3399 
Mabena porridge SUrf, coarse, fine 3437 
Oats porridge Brand name: 3239 
Breakfa:st ce.reals Puffe<l Wheat, plain 3325 
Puf~ed wheat, sweet 
Com Flakes, plain 3243 
Wee! Bix 3244 
purred Rice, sweet 3372 
Rice crispies 3252 
Pronulro, plain 3245 
Pronutro, High fibre 3436 
Muesli 3303 
Specify types usually eaten 
Brand names of cereals 
avaiJable a! home now: 
Milk on porridge or None 
cereal: VVhole/fresh 2718 
Circle Iype:usu<llly sour 2787 
used: 251011 2772 
Fat Ireel skimmed 2775 
Milk blend 2m 
Soy milk 2737 
Condensed (whole, sweet) 2714 
Condensed (s;kim, sweet) . 2744 
~vaporaled whole 2715 
Evaporated low lal 2827 
NOI'I-dairy creamer 275\ 
Is sugar added to None 
porridge or cereal? While 39a9 
(tick box) Brown 4005 
syrup 39M 
Honey 3984 
SWeelner: type 
. 
Is fat added to None 
porridge or cereal? Animal fal (butter) 3479 
(Uck box) Hard ma~gatltle 3484 
Soft marg~r,i~ 3496 
on 3507 
Peanut butter 3485 
Sampl Maize Ticl! !'ought 3250 
Self ground 3725 
Samp and beans Specify ratio (\:\) 
-
3402 
Samp and peanuts '5 pecify ratio 
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I AMOUNT TIMES EATEN I 
FOOD DESCRIPTION USUALLY CODE AMOUNT/DAY 
EATEN p" p" Seldomln Per day 
week month ever 
Rice: specify brands While 3247 
Names: Elrown 3315 
Sorghum rice 3437 
Stamped wheal 3249 
Pastas Macaroni 3262 
spaghenj 3262 
Spaghetti in tomato sauce 3258 
, Other: 
, 
i Brp_2d/Bread rolls While 3210 
Bread slices:Jh[o. Brown 3211 
Medium. thick whole wheat 3212 
Other breads Specify types, e.g. 
Raisin 3214 
Maize Meal 3278 
Sweelcorn 3379 
Ry, 3213 
Olher" 
PiZZa !spedfy Cheese, tomato & onion 3353 
I~ppings) 
Hoi dogs (spe<:ily 
sausage) 
Hamburger (speci~y 
meal)" 
Are any of the Buller 3479 
following spread s Bullo 3523 
'used on bre01d? Ammallallbeel Jallow) 3494 
(tick bo~) Lard 3495 
Hard margarine (brick) '3484 
Sofl marganne {light) 3496 
Cookmg fal 3~16 
Peanut butter 3485 
Sweet spreads J,m 3985 
Syrup 3988 
honey 3964 
Marmitel 4030 
OXOI 4029 
8o\ltil 4029 
Fish paste . 3109 
Meal paste 2917 
Cheese Specify types: 
Cottage low~fat. cheese 2760 
Cream ch~sl! Tl25 
Gouda-- 2723 
Cheddar 
-
2712 
.-
. Other: 
.. 
Cheese spreilds Lowfal 4310 
Full rat 2730 
Specify types: 
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AMOUNT TIMEs EATEN 
FOOD DESCRIPTION USUALLY CODE AMOUNTIOAY 
EATEN Por Por Seldomln Per day 
week month ever 
I Atchar 3117 
other spreads: 
(Specify types) 
Dumpling 3210 
Vetkoek 3257 
Provi!a 3235 
Crackers R~fined 3331 
Whole wheat :1391 
Rusks - Commercial eran 3330 
Buttermilk 3329 
White 3364 
Boerebeskuli. while 3364 
Home-made AH-br.m 3380 
RaisIns 3380 
Buttermilk. whlle 3215 
Buttermilk. whole wheat 3255 
Olher, specify 
Scones 3237 
Muffins Plain 3408 
Bran 3407 
HOW MANY TIMES A DAY DO YOU EAT BREAD? 
AMOUNT TIMES EATEN ; 
FOOD DESCRIPTION USUALLY CODe AMOUNT/DAY ! Por Por Seldomln 
, EATEN Per day week month ever , 
Chicken Soiled wilh skin 2926 
Wilhout skin 2963 
00 you ~at the Fried: in batler/crumbs 3018 
chicken with the Fri~ but not coated 2925 
skin? n 
n 
Roasted/grilled - with skin 2925 
Yes No Hoasledlgrilled - without skin 2950 
Chicken bones stew A003 
, Chicken heads, raw 2999 
i Chicken stew, 
I 
with veg & skin 3005 
Chicken offal Giblets 2998 
, Chicken pie Commercial 2954 , 
, Home-made 2954 
i Red meat: Beef Fried/grilled: with fat 2908 
without fat 2959 
! 
Stewedlboiled: with rat 3006 , 
without fat 2909 
Mince witt'- tomato & onion 2987 
, Mina!-: curry 
-
3015 
. Meatball regular 2966 
.. lean 3034 
Red meat: Mutton Fried/grilled: with fat 29Zl 
without fat . -2934 
StewedlboiJed: with fat - :io4o 
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AMOUNT TIMES EATEN I 
FOOD DESCRIPTION USUALLY CODE AMOUNTIOAY 
EATEN p" p" Seldomln Per day 
week monlh ever 
""';Ihout ral 2916 
Red meat: Pork Friedlgrilled: with fat 2930 
....,;thout rat 29n 
SlewediboUed: 'Nith fat 3046 
without rat 3045 
Crumbed/Schnitzel 2952 
Red meat: Goal Fried/grilled: with fat 4281 
without lal 
Stewed/boiled: plain 4'281 
with veg 4282 
Offal : Intestines: boiled, nolhing 3003 
addtd 
Specify ty pe: MVetdermM Ined 3003 
Stewed with vegetables 
liver 2955 
Kidney 2956 
TrIpe Mpens" troners, head 3003 
Pluck (lungs, heart, gullet) 3019 
Specify vegetables 
used in me'll slews 
(only if nol 
mentioned 
elsewhere ) 
Wors/sausilge Flied 2931 
Bacon 2906 
Cold me.3.l s POlony 2919 
Hom 2967 
Vienna's canned 2936 
Russian 2948 
Frank/utter 2937 
Other (sped/y) 
.C.;anned meat BUUy beel 2940 
Other (specify) 
Meat pie , Bought 2939 
Billong Beer with fat 2911 
fat trimmed 3021 
wOree wars- 1949 
Legumes: Slews & curries (speci fy) 
spec::ify dried beansl Soups 3157 
." [ 
;-.. , 
pe:asJlentlls Satads 3174 
" 
Baked beans 3176 
0 
" 
Soya pro'duds e.g, Brands at home now 
Don't know 
" 
-- -
Toppers Shew examples 3196 
Imana 
- " 
Frie.d fish (fresh or With batter/crumbs 3072 "-,, 
frozen fried In sun 
-' 
Without batter/crumbs 
- ' 
3060 Ii 
oil) ..  _. ,j, , 
-
._ ' .. MO· '- , 
Fresh water fish Specify cooking method 3094 
Specify type Medium fal. batter, fried 
-
-~-' 
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AMOUNT 
FOOD DESCRIPTION USUALLY 
EATEN 
Canned nsh: 
-
Pilchards In brine 
In lomato sauce 
Mash~ wilh fri1!!d onion 
Sardines In oil 
In !Clmalo sauce 
Tuna In oil 
In bnne 
Mackerel 
Salmon 
Pickled fish/curried 
Fish cakes Fried: oillbunerlmargarine. 
Specify canned or commercial 
o ther 
Sailed dried !'ish 
Eggs BOIled/poached 
Scrambl~: In oil 
in butter 
in margarine 
Fried: In oil 
in buller 
in marganne 
in bacon ral 
CUrried 
HOW MANY TIMES A WEEK 00 YOU EAT: MEAT 
BEANS 
CHICKEN 
FISH 
EGGS 
AMOUNT 
FOOD DESCRIPTION USUALLY 
EATEN 
CABBAGE Boiled. nothing added 
Boijed with polato, onion, ral 
Fried. in margarine (nothing 
odd"') 
Fried, in oil (nothing ;added) 
Boiled , then fried with potato 
and onion 
Other: 
-
Spinach/morogo' Bailed, nothing added 
imfinol other greem Boiled rat added (margarine) 
leaty vegetables: Boiled with onionltomato, fat 
List namu: • arion & ·Pot!l to (margarine) 
. 
• onion, tomalo & potato 
- with peanuts 
Qther: 
Tomato and onion Home made with fal 
gravy'lrelish/chow without rat 
TIMES EATEN 
CODE AMaUNTfDAY 
Per Per Seldornln Per day 
week month ever 
3055 . 
3102 
AOOS 
0087 
J087 . 
3093 
3054 
3113 
3101 
3076 
3080 
2867 
2876 
2889 
2886 
2887 
2869 
2868 
28n 
287Q 
2902 
_____ ANO 
_____ 7 
TIMES EATEN 
Per Po. Seldomln CODE AMOUNT/DAY 
P1!!rd;ay 
week month ever 
3758 
3813 
3810 
3912 
AOO6 
3913 
3898 
AO" 
3901 
3910 
- 3925 
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AMOUNT TIMES EATEN 
FOOD DESCRIPTION USUALLY CODE AMOUNT/DAY 
EATEN p" p" Seldomfn Per day 
week month ever 
Canned 4129 
Pumkin Cooked in fat and sugar 3893 
Specify Type: Boiled, little sugar and fat 
Balled 4164 
Olher: 
CCirrois Boiled sugar & fat 3819 
Boiled nothing added 3757 
Boiled, potalo, onion, no fat 3934 
Boiled, potato, onion, margarine 3822 
Boiled, with sugar 3818 
Raw, salad (orange juice ) 3711 
Chakalaka 
Other: 
Mealiesl On cob 3725 
Sweet corn Off cob - creamed sweetcorn 3726 
Ofr cob - whole kernel 3942 
Beetroo{ Cooked · 3698 
i Salad (bought or home made) 3699 
I 
Potatoes Boiled with skin 4155 
without skin 3737 
I , Baked in skin (nesh and skin) 3736 
I 
Baked in skIn (flesh only) 3970 
Mashed · skIm mIlk, marganne 3875 
""",h',,1 • whel. mUk, fT1l1 rO llrln. U7' 
Roasted In beef fat 3878 
French fries/potato chips (oil) 3740 
Salad (mayonnaise and egg ) 3928 
Other: 
Sweet potatoes Boiled with skin 3748 
, without skin 3903 
Baked 'NiIh skin (flesh only) 3748 
without skin 3903 
Mashed 3903 
Mashed with fat & sugar 3749 
Other: 
Peas GrlM!n, frozen 4146 
Green, frozen with sugar 3nO 
Wlth sugar and butter 3859 
Tinned peas 4149 
Green peppers Raw 3733 
Cookl!d (stew with oil) 3865 
BrinjaUegg plant Cook~ 3700 
Fried inoi! 3802 
St~w (oil, [pr:oalo, onion) 3798 
Mushrooms Raw , • • 0 
-
3842 
S'!utiled in bnck marganne 3839 . 
., 
Sauteed In oil 3841 
Onions Sauteed in sun oil 3730 
S~uti!:ed In margarine 3844 
: Salad vegetables Rawtomaio - 3750 
Lettul:e 3723 
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·" AMOUNT TIMES EATEN 
FOOD DESCRIPTION US UALLY CODE AMOUNTIOAY 
EAT EN p" p" SeldorrJn Per day 
week month ever 
Cucumber I 3718 
Avocado's 3656 
Green Beans Boiled nothing added 3696 
Cooked, potato, onion, 3792 
margarine 
Cooked, potato, onion, no fat 3933 
CauUTlower Bolh!!d 3716 
Other vegetables 
speci fy 
It you fry veg or add Butter 3479 
fat specify type or Bulro 3523 
fa t usu ally used Animal fat (beef tallow) 3494 
(tick box) laId 3495 
Hard margarine (brick) 3484 
son margarine (tub) 3496 
son margarine (light) 3524 
Sunflower oil 3507 
HOW MANY TIMES A WEEK 00 YOU EAT VEGETABLES? 
AMOUNT TIME S EATEN 
FOOD DESCRIPTION USUALLY p" Per Seldomln CODE AMOUNT/DAY 
EATEN Per day week month ever 
Mayonnaise! Mayonna1se: Bought 3488 
home-m ade 3506 
Salad dress ing Cooked said dressing 3503 
$;!lad dressmg low-oil 3505 
S;!!ad dreSSing French 3487 
Oil: Olive 3509 
Oil: Sunflower 3507 
Oil: Canola 4280 
Apples Fresh 3532 
CaMed, unsweetened 4216 
Pears Fresh 3582 
Canned, in syrup 3583 
Bananas 3540 
Oranges 3560 
Naartjies 3558 
Grapes 3550 
Peaches F.rcsh 3565 
Canned. in syrup 3567 
A prico ts F.rcsh 3534 
Canned, in syrup 3535 
Mangoes " Frl!sn 355. 
Pawpaw Raw ~ 3563 
Pine'apple Raw 3581 
. Canned. in syrup 3648 
Guav4lIs Fresh 3551 
Canned,"in syrup 3553 
" Watermelon 3S76 
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I 
AMOUNT TIMES EATEN 
FOOD DESCRIPTION USUALLY CODE AMOUNTIOAY 
EATEN Por Por SeJdomln Per day 
week month ever 
Spanspek Orange flesh 3541 
Gre!!n flesh 3575 
wild fruit/berries 
(Specify types ) 
Dried fruit (also as Raisins 3552 
snacks) Prunes (raw) 3596 
Prunes (COoked with sugar) 3564 
Peaches (taw) 3568 
Peaches (ccok ed with sugar) 3569 
Apples (rawl 3600 
Dned fruit sweets 3995 
Other' 
Olher Iruil 
, 
i 
HOW MANY TIMES A WeEK 00 YOU EAT FRUITS? 
i we NOW WILL ASK YOU QUESTIONS ABOUT WHAT YOU USUALLY ORINK 
AMOUNT TIMES EATEN 
FOOD DESCRIPTION USUALLY Per Por 1 Seldomln CODE AMOUNTIDAY 
, EATEN Per day week month ever , 
~ Waler 4042 
, Tea Ceylon , «l38 
Rooil)os 4054 
: Coffee <0037 
i Sugar per cup of While 3989 
tea or coffee Brown 4005 
Milk per cup of tn FreshlLonglife 2718 
or coffee Fresh longtife 2% 7:T72 
. What ype of milk Goal " - 2738 
do you put in tea FreshlLonglireJFat free 2775 
.. (skimmed milk) 
Whole milk powder 263' 
Reconstituted 
r I Sp«:iIy b .. nd 
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AMOUNT TIMES EATEN I 
FOO~ DESCRIPTION USUALLY coDe AMOUNT/DAY 
EATEN Por Pe, Seldomln Per dOJy 
week month I!ver 
Skimmed milk powder 2719 
Reconstituted 
Soecify brand 
Milk blend, reconstituted 2m 
Specilv brand 
Whitener/non-dOJiry creamer 2751 
Specify brand 
Condensed milk (whole) 2714 
Condensed milk (skim) 2744 
Evapcrate::l milk (whole) 2715 
EV<lporated milk-flow lal) 2827 
None 
Milk a such: Freshllong life! whole 2718 
Wh<Jt ty pe 0' milk do FtesMong life/2°J:. 2n2 
yo u drink as such? Frestvlonglifelfat Iree(sklmmedl 2nS 
Goat 27'8 
Sour I Maas 2787 
Buttermilk 2713 
Milk drinks NesUi! - nesQulk 4287 
Speci fy brands, Milo 2735 
including milk Flavoured milk 2n< 
Supplements and 
Iype of milk used Olher 
Yoghurt Drinking yoghurt 2756 
Thier. yoghurt. plain. lruit 2732 
Squash SixO ,gOO 
Oros '982 
Ltcol with sugar 3982 
Lecol with artificial S'M!elner '990 
Kool Aid '982 
Othf!r: 
Fruit juice Fresh! UquifruitICeresi 2866 
"Tropica-/mixturl!s with milk 2791 
Fruit syrups Average ·2865 
Guava syrup 2864 
Fizzy drink Sweetened 3981 
Coke, Fanta Diet 
.-
3990 
MageulMotogo sorghum bee[ <055 
Alcoholic beverages Specify: 4039 
such as sorghum 
beer~ 
Other. specify: Beer average 4031 
Wine .,:em 
Cider '4057 
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AMOUNT TIMES EATEN 
FOOD DESCRIPTION USUALLY CODe AMOUNTIOAY 
EATEN p" Per Seldomln Per day 
week month ever 
Spiritus, e,g brandy, whisky, 4035 
gin, vodka 
Liaueur 4055 
Other: 
PLEASE INDICATE WHAT TYPES AND AMOUNTS OF SNACKS, PUDDINGS AND SWEETS YOU EAT: 
AMOUNT TIMES EATEN 
FOOD DESCRIPTION USUALLY Per Per Seldomln CODE AMOUNTIDAY 
EATEN Per day week month ever 
Potato crispS/chips 3417 
Peanuts Roasted, unsaUed 3452 
Roasled, salted 3<058 
Cheese curls: Average 326; 
Niknaks, etc. Savoury 3<018 
Popc orn Plain Ino salt and butter) 3332 
Plain (salt and bu"er added) 
Sugar coated 3359 
ROIisins (seed s) 4231 
Chocolates Milk 3987 
Kit Kat 402' 
Peppermmt CriSp 3997 
Spe>:lfy types and names: 
Candies Suqvs, gums, hard sweets 3986 
(specify) 
Pl!ppermmt 4004 
Sweets Torr~s 3991 
Hard boil~ 3986 , 
Fudge, caramels (specify) 3991 ' 
Biscuits/cookies 5pedfy""": 
Home made pl3in 3233 
shortbread, butter 3296 
Commen::ial, plain 3216 
Commercial, with filling 3217 
Cakes and tarts Chocolate, plain 341' 
Panc;Jkesierumpels 3344 
Koeksisters 3231 
S.oIvouries Scll.JSilgerolls . 2!l3' 
S~m0us:3S • vegetable 3414 
.. SamolJSas • mutton = 
.. Biscl.rit$ e,g, baC(ln kips 3331 
other: 
. 
Pudding: jellV -3983 
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AMOUNT TlMES EATEN I 
Faoe DESCRIPTION USUALLY CODE AMOUNilDAY 
EATEN Pe, Pe' SeldomJn Per day 
week month ever 
Baked pUdding I PlaIn baner 3429 
Instant pUdding Skim milk I 3314 
Whole milk 3266 
Ic~ cream Commercial regular 3483 
Commercial rich 3519 
Soft serve 3518 
Somet 3491 
Ice loflies 3982 
Chocolate cO<lted individual 
ice creams (e.g. Magnum) 
Custard Home made, whote milk 27 16 
Ullramel 2716 
35201 
Cream Fresh 3480 
Other puddings 
(Specify) 
HOW MANY TIMES A WEEK 00 YOU EAT SNACK FOODS? 
SAUCES 1 GRAVIES 1 CONDIMENTS 
AMOUNT TIMES EATEN 
FOOD DESCRIPTION USUALLY p" Poe SeldomJn CODE AMOUNT/DAY 
EATEN Per day week month ever 
Tomato sauce 3139 
Worcester sOluce 4309 
Chutney FrUIt 3168 
Tomalo 3114 
Pickles 3866 
Packer scups 3158 
Bee! stock 4029 
Chicken stock 4029 
Others: 
I WILD BIRDS, ANIMALS, rSECT~ OR FRU1TS AND BERTS Ihunled o( co"eCl ;n 'Ul ""'1' on fann, redly) I 
PLEASE MENTION ANY 01l-1ER FOODS YOU EAT MORE THAN ONCE EVE~Y ~O WEEKS WHICH WE HAVE NOT TALKED 
ABOUT AND OR FOODS EATEN IN OTHER HOMES OR PLACES CURING THE PAST WEEK 
----
AMOUNT TIMES EATEN 
-FOOD DESCRIPTION USUALLY Pe, Pe, Seldomln eOCE AMOUNTIOAY 
---
-
EATEN Per day week month ever 
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AMOUNT TIMES EATEN 
FOOD oeSCRIPTION USUAllY 
EATEN 
Per dayj Per I Per : I SeldomJn 
w~k month ever 
ARE THERE ANY FOODS THAT YOU EAT WHICH WE HAVEN, TALKED ABOUT? PLEASE USTTHEM. 
FOOD 
AMOUNT TIMES EATEN 
DESCRIPTION USUALLY p., p" 
EATEN Per day week monlh 
THANK YOU FOR YOUR CO~PERAT10N AND PATIENCE 
GOOD BYE! 
Setdomln 
ever 
CODE AMOUNTIDAY 
COOE AMQUNTIDAY 
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APPENDIX: 4 
OUESTIONNAIRE FOR SUBJECTS WHO COMPLETED THE 
STUDY 
Please answer the following questions regarding your participation in the research study: 
Respondent number: 
Surname and Initials: 
Employee Number: 
Date of Birth: 
1. Did you experience any vomiting during the study? 
1. Yes 2. No 
If yes, how many times? 
1. After each meal 2. Once a day 3. Once a week 
4. Other 
2. Did you experience any flatulence during the study? 
1. Yes 2. No 
If yes, how many times? 
1. After each meal 2. Once a day 3. Once a week 
4. Other 
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3. Did you experience any stomach cramps during the study? 
1. Yes 2. No 
If yes, how many times? 
1. After each meal 
4. Other 
2. Once a day 3. Once a week 
4. Did you experience any changes in your lifestyle during the study? 
1. Yes 2. No 
If yes, describe the changes: 
5. Did you experience any constipation during the study? 
1. Yes 2. No 
If yes, how frequent? 
1. After each meal 
4. Other 
2. Once a day 
6. Did you experience an increased appetite during the study? 
1. Yes 2. No 
If yes, explain: 
3. Once a week 
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7. Did you experience any changes in your alcohol consumption during the study? 
1. Yes 2. No 
If yes, to what extent? 
8. Did you use any medication/supplements during the study? 
1. Yes 2. No 
If yes, what is the name of the medication/supplement you used? 
If yes, how many times did you use this medication/supplement? 
1. After each meal 2. Once a day 3. Once a week 
4. Other 
and for how long (days)? 
9. Did you consume all of the experimental capsules every day? 
1. Yes 2. No 
10. Was the amount of capsules consumed acceptable? 
1. Yes 2. No 
11. Would you be willing to consume these capsules daily if they are considered as 
healthy? 
1. Yes 2. No 
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12. Did you experience any other side-effects of the supplement during the study? 
1. Yes 2. No 
If yes, please specify? 
If yes, how frequent? 
1. After each meal 2. Once a day 3. Once a week 
4. Other 
13 . Did you experience any positive effects on your health during the study? 
1. Yes 2. No 
If yes, explain. 
14. Do you have any other comments you would like to make regarding the study? 
The research team would like to thank you for your co-operation during the study. The 
project is very important for gaining new scientific knowledge. 
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